WO2000010500A1 - Article absorbant protegeant et ameliorant la sante cutanee - Google Patents

Article absorbant protegeant et ameliorant la sante cutanee Download PDF

Info

Publication number
WO2000010500A1
WO2000010500A1 PCT/US1999/019571 US9919571W WO0010500A1 WO 2000010500 A1 WO2000010500 A1 WO 2000010500A1 US 9919571 W US9919571 W US 9919571W WO 0010500 A1 WO0010500 A1 WO 0010500A1
Authority
WO
WIPO (PCT)
Prior art keywords
absorbent article
skin
absorbent
calculated according
defines
Prior art date
Application number
PCT/US1999/019571
Other languages
English (en)
Inventor
Susan Carol Paul
Frank Jerrel Akin
Robert Cosmo Di Luccio
Dennis Stein Everhart
Elizabeth Deibler Gadsby
Pamela Jean Mayberry
Audra Stefanik Wright
Ali Yahiaoui
Michael John Faulks
Duane Gerard Krzysik
Karen Marie Menard
David Charles Musil
Frank Andrew Rosch, Iii
Gordon Allen Shaw
David John Tyrrell
Diane Michele Underhill
Jeffrey Michael Hockersmith
Gunilla Elsa Gillberg-La Force
Wade Bolton May
Original Assignee
Kimberly-Clark Worldwide, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/139,820 external-priority patent/US6152906A/en
Priority claimed from US09/298,314 external-priority patent/US6149934A/en
Priority claimed from US09/328,681 external-priority patent/US6287286B1/en
Priority claimed from US09/343,861 external-priority patent/US6497893B1/en
Priority claimed from US09/377,294 external-priority patent/US6448464B1/en
Priority claimed from US09/379,431 external-priority patent/US6217890B1/en
Priority to KR1020017002351A priority Critical patent/KR20010085581A/ko
Priority to BR9913236-2A priority patent/BR9913236A/pt
Priority to JP2000565825A priority patent/JP2003526390A/ja
Application filed by Kimberly-Clark Worldwide, Inc. filed Critical Kimberly-Clark Worldwide, Inc.
Priority to EP99967816A priority patent/EP1107719A1/fr
Priority to AU60210/99A priority patent/AU748171B2/en
Publication of WO2000010500A1 publication Critical patent/WO2000010500A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/48—Surfactants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/15203—Properties of the article, e.g. stiffness or absorbency
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/34—Oils, fats, waxes or natural resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/15203—Properties of the article, e.g. stiffness or absorbency
    • A61F2013/15284—Properties of the article, e.g. stiffness or absorbency characterized by quantifiable properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F13/534—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad
    • A61F13/537—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad characterised by a layer facilitating or inhibiting flow in one direction or plane, e.g. a wicking layer
    • A61F2013/53795—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad characterised by a layer facilitating or inhibiting flow in one direction or plane, e.g. a wicking layer being a surge management layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents

Definitions

  • the present invention relates to an absorbent article for absorbing body fluids and exudates, such as urine. More particularly, the present invention relates to absorbent garments, such as disposable diapers and adult incontinence garments, which are configured to absorb body exudates while maintaining or improving the health of the wearer's skin.
  • absorbent article configurations employ absorbent materials located between a liquid pervious topsheet and a liquid impermeable backsheet.
  • Such backsheets are well suited to prevent the migration of liquid waste from the absorbent materials to the outer garments of a wearer.
  • the use of such articles and , in particular, such articles which include a liquid and vapor impermeable backsheet can result in a high degree of humidity within the diaper when in use which may increase the temperature of the wearer's skin and result in relatively high skin hydration levels. Such conditions can lead to a reduction in the health of the wearer's skin.
  • the occlusive, moist environment inside absorbent articles incorporating such backsheets can promote the viability of microorganisms, including Candida albicans, which can undesirably lead to the onset of dermatitis such as what is commonly referred to as diaper rash.
  • the liquid pervious topsheets on such articles have typically been constructed of nonwoven materials such as spunbond polyolefin materials. Unfortunately, such materials do not always provide a soft, nonabrasive contact with the skin.
  • the wearer's skin can become quite irritated and red particularly in the presence of urine and feces. The abrasion resulting from such topsheets and the presence of urine and feces can also undesirably lead to the onset of dermatitis.
  • Diaper dermatitis can afflict almost every infant at some time during the diaper wearing years. The most severe form of this condition is usually caused by secondary infection with the fungi Candida albicans. Although other factors influence the pathogenesis of this fungi, one critical factor is the relative humidity within the diaper which is directly related to the occlusion or semi-occlusion of the diaper area.
  • breathable polymer films have been employed as outer covers for absorbent garments, such as disposable diapers.
  • the breathable films are typically constructed with micropores to provide desired levels of liquid impermeability and air permeability.
  • Other disposable diaper designs have been arranged to provide breathable regions in the form of breathable panels or perforated regions in otherwise vapor-impermeable backsheets to help ventilate the garment.
  • the caregiver often applies skin protective products directly to the skin of the wearer before positioning the article on the wearer.
  • skin protective products have included petrolatum, mineral oil, talc, corn starch, or various other commercially available rash creams or lotions. This procedure typically involves the caregiver applying the products to their hand and then transferring the products to the wearer's skin.
  • some conventional absorbent articles have included lotion formulations applied to the topsheet such that, in use, the formulations transfer to the skin or provide lubricity thereby reducing the friction between the topsheet and the skin.
  • lotion formulations have been unstable and tended to migrate away from the surface of the topsheet into the topsheet and absorbent core of the absorbent articles leaving less on the surface to transfer to the skin or provide the reduced abrasion. This migration problem is particularly evident at higher temperatures such as those at the skin surface in use or those in typical storage conditions in warm climates.
  • lotions which have been incorporated on the topsheets of such articles have migrated such that a less effective amount has been applied to the wearer's skin or been located between the skin and the topsheet in use.
  • large amounts of such lotions have been required to be added to the topsheet to deliver the skin benefit.
  • the wearer's skin has remained susceptible to rashes, abrasion and irritation. Accordingly, there remains a need for absorbent articles which maintain or improve skin health.
  • Such absorbent articles may have a high air exchange rate when wet, maintain skin temperature when wet, have reduced levels of skin hydration, include a lotion formulation or treatment composition which provides a skin health benefit, and/or have a reduced viability of microorganisms.
  • air exchange refers to the transfer of air and, in particular, humid air from the interior of an absorbent article, when in use on a wearer, to the exterior of the absorbent article (ambient atmosphere) which allows drier ambient air to move into the absorbent article.
  • a substantially liquid impermeable material is constructed to provide a hydrohead of at least about 60 cm (centimeters), desirably at least about 80 cm, and more desirably at least about 100 cm.
  • a suitable technique for determining the hydrohead value is the Hydrostatic Pressure Test which is described in further detail herein below.
  • a substantially vapor permeable material is constructed to provide a water vapor transmission rate (WVTR) of at least about 100 g/sq.m/24 hr, desirably at least about 250 g/sq.m/24 hr, and more desirably at least about 500 g/sq.m/24 hr.
  • WVTR water vapor transmission rate
  • a suitable technique for determining the WVTR value is the Water Vapor Transmission Rate Test which is described in further detail herein below.
  • viscosity refers to the viscosity in centipoise determined according to ASTM D3236, entitled “Standard Test Method for Apparent Viscosity of Hot Melt Adhesives and Coating Materials.”
  • melting point refers to the temperature at which the majority of the melting occurs, it being recognized that melting actually occurs over a range of temperatures.
  • melt point viscosity refers to the viscosity of the formulation at the temperature at which the majority of the melting occurs, it being recognized that melting actually occurs over a range of temperatures.
  • penetration hardness refers to the needle penetration in millimeters according to ASTM D 1321 , “Needle Penetration of Petroleum Waxes.” Lower needle penetration hardness values correspond to harder materials.
  • z-direction migration loss refers to the value obtained when subjecting an absorbent article having a lotion formulation on the bodyfacing surface thereof to the Z-Direction Lotion Migration Test set forth below.
  • cd-direction migration loss refers to the value obtained when subjecting an absorbent article having a lotion formulation on the bodyfacing surface thereof to the CD-Direction Lotion Migration Test set forth below.
  • the present invention relates to an absorbent article which comprises an absorbent, a front waist section, a rear waist section and an intermediate section which interconnects the front and rear waist sections.
  • the absorbent article defines a Wet Air Exchange Rate of at least about 190 cubic centimeters per minute calculated according to the Tracer Gas Test set forth herein.
  • the article defines a Wet Air Exchange Rate of at least about 200, desirably at least about 225 and more desirably at least about 250 cubic centimeters per minute calculated according to the Tracer Gas Test.
  • the absorbent article may further define a Dry Air Exchange Rate of at least about 525 cubic centimeters per minute calculated according to the Tracer Gas Test and/or a Skin Hydration Value of less than about 18 grams per square meter per hour calculated according to a Skin Hydration Test set forth herein.
  • the present invention relates to a disposable absorbent article which comprises an absorbent, a front waist section, a rear waist section and an intermediate section which interconnects the front and rear waist sections.
  • the absorbent article defines a Skin Hydration Value of less than about 18 grams per square meter per hour calculated according to the Skin Hydration Test set forth herein.
  • the absorbent article may define a Skin Hydration Value of less than about 15, desirably less than about 12 and more desirably less than about 10 grams per square meter per hour calculated according to the Skin Hydration Test.
  • the absorbent article may further define a Wet Air Exchange Rate of at least about 190 cubic centimeters per minute and/or a Dry Air Exchange Rate of at least about 525 cubic centimeters per minute calculated according to the Tracer Gas Test as set forth herein.
  • the present invention relates to a disposable absorbent article which defines a front waist section, a rear waist section, and an intermediate section which interconnects the front and rear waist sections.
  • the absorbent article includes a) a vapor permeable backsheet which defines a Water Vapor Transmission Rate of at least about 1000 grams per square meter per 24 hours calculated according to a Water Vapor Transmission Test as set forth herein; b) a liquid permeable topsheet which is positioned in facing relation with the backsheet; and c) an absorbent body located between the backsheet and the topsheet which may define multiple zones of high air permeability for improved air exchange.
  • the zones of high air permeability in the absorbent body define a Frazier Porosity which is at least about 10 percent greater than a Frazier Porosity of portions of the absorbent body adjacent to the zones of high air permeability.
  • the absorbent article may further include a ventilation layer located between the backsheet and the absorbent body.
  • the present invention relates to a disposable absorbent article which defines a front waist section, a rear waist section, and an intermediate section which interconnects the front and rear waist sections.
  • the absorbent article includes a) a vapor permeable, liquid impermeable backsheet which defines a Water Vapor Transmission Rate of at least about 1000 grams per square meter per 24 hours calculated according to a Water Vapor Transmission Test as set forth herein; b) a liquid permeable topsheet which is positioned in facing relation with the backsheet; c) an absorbent body located between the backsheet and the topsheet; d) a ventilation layer located between the backsheet and the absorbent body; and e) a surge management layer located between the topsheet and the absorbent body.
  • the absorbent body of the absorbent article includes a plurality of zones of high air permeability for improved air exchange which define a Frazier Porosity which is at least about 10 percent greater than a Frazier
  • the present invention relates to a disposable absorbent article which includes an absorbent, a front waist section, a rear waist section and an intermediate section which interconnects the front and rear waist sections.
  • the absorbent article defines a C. albicans viability which is less than about 85 percent of the C. albicans viability of a control calculated according to a C. albicans Viability Test as set forth herein.
  • the C. albicans viability is less than about 80 percent and desirably less than about 60 percent of the C. albicans viability of the control calculated according to the C. albicans Viability Test.
  • the absorbent article may further define a Wet
  • the present invention relates to a disposable absorbent article which comprises an absorbent, a front waist section, a rear waist section and an intermediate section which interconnects the front and rear waist sections.
  • the absorbent article defines a Wet Skin Temperature/Dry Skin Temperature Ratio of no more than about 1.010 calculated according to a Skin Temperature Test as set forth herein.
  • the absorbent article defines a Wet Skin Temperature/Dry Skin Temperature Ratio of no more than about 1.005, desirably no more than about 1.000, more desirably no more than about 0.995, and even more desirably no more than about 0.990 calculated according to the Skin Temperature Test.
  • the absorbent article may further define a Wet Air Exchange Rate of at least about 190 cubic centimeters per minute and/or a Dry Air Exchange Rate of at least about 525 cubic centimeters per minute calculated according to the Tracer Gas Test as set forth herein and/or a Skin Hydration Value of less than about 18 grams per square meter per hour calculated according to the Skin Hydration Test set forth herein.
  • the present invention resides in an absorbent article having a topsheet which includes a lotion formulation or treatment composition on the outer bodyfacing surface thereof.
  • the topsheet includes a lotion formulation comprising from about 5 to about 95 weight percent of an emollient, from about 5 to about 95 weight percent of a wax, and, optionally, from about 0.1 to about 25 weight percent of a viscosity enhancer.
  • the lotion formulation may be applied by known methods in the art such as spraying, slot coating or printing to the topsheet at a temperature no more than about 10°C above a melting point of the lotion formulation to reduce migration of the lotion formulation on the topsheet.
  • the emollient is selected from the group consisting of oils, esters, glycerol esters, ethers, alkoxylated carboxylic acids, alkoxylated alcohols, fatty alcohols and mixtures thereof.
  • the wax is selected from the group consisting of animal based waxes, vegetable based waxes, mineral based waxes, silicone based waxes and mixtures thereof all of which may be natural or synthetic.
  • the lotion formulation includes from about 5 to about 95 weight percent of petrolatum, from about 5 to about 95 weight percent of a wax selected from the group consisting of animal based waxes, vegetable based waxes, mineral based waxes, silicone based waxes and mixtures thereof all of which may be natural or synthetic and from about 0.1 to about 25 weight percent of a polyolefin resin, all based on the total weight of the lotion formulation.
  • the present invention resides in an absorbent article having a topsheet which includes a treatment composition on the outer bodyfacing surface thereof.
  • the treatment composition includes a surfactant and a skin health benefit agent, preferably as an emulsion such as an oil-in-water emulsion.
  • the skin health benefit agent may include zinc compositions.
  • the treatment composition may also include a protein such as silk proteins like sericin.
  • the various aspects of the present invention advantageously provide an absorbent article with maintain or improve the health of the wearer's skin.
  • such improved absorbent articles may exhibit substantially reduced levels of hydration of the wearer's skin when in use compared to conventional absorbent articles.
  • the reduced level of skin hydration promotes drier, more comfortable skin and renders the skin less susceptible to the viability of microorganisms.
  • wearer's of absorbent articles made according to the present invention have reduced skin hydration and more constant skin temperatures in use which can lead to a reduction in the incidence of skin irritation and rash.
  • the lotionized or treated topsheet provides a soft, smooth contact with the wearer's skin and reduced levels of skin irritation.
  • the lotion formulations applied to the topsheet are more stable and have a higher viscosity than conventional lotion formulations, particularly at higher temperatures, a greater percentage of the added lotion remains on the surface of the topsheet where it can readily contact and transfer to the wearer's skin to provide the benefit.
  • a lower amount of the lotion formulation can be added to the topsheet to provide the same benefit at a lower cost due to the localization of the lotion at the surface of the topsheet.
  • the skin of the wearers of the absorbent articles of the present invention may be less susceptible to rashes, abrasion and irritation.
  • Fig. 1 representatively shows a partially cutaway, top plan view of an absorbent article according to one embodiment of the invention
  • Fig. 2 representatively shows a sectional view of the absorbent article of Fig. 1 taken along line 2-2.
  • Fig. 3 representatively shows a partially cutaway, top plan view of an absorbent body for an absorbent article according to another embodiment of the invention
  • Fig. 4 representatively shows a sectional view of the absorbent body of Fig. 3 taken along line 4-4.
  • Fig. 5 representatively shows a partially cutaway, top plan view of an absorbent body for an absorbent article according to another embodiment of the invention
  • Fig. 6 representatively shows a sectional view of the absorbent body of Fig. 5 taken along line 6-6;
  • Fig. 7 representatively shows a graph of the data from Example 15 and Comparative Example 6;
  • Fig. 8 representatively shows the test apparatus for the Lotion Migration Test set forth herein;
  • Figs. 9-13 representatively show the results from Examples 17-21. Detailed Description of the Invention
  • the absorbent articles of the present invention advantageously maintain or improve the health of the wearer's skin.
  • the absorbent articles may exhibit a substantially reduced level of hydration of the wearer's skin in use when compared to conventional absorbent articles.
  • the absorbent articles of the present invention may further maintain a more constant temperature of the wearer's skin when wet when compared to conventional absorbent articles.
  • wearer's of absorbent articles of the different aspects of the present invention have reduced skin hydration which renders the skin less susceptible to the viability of microorganisms which can lead to a reduction in the incidence of skin irritation and rash.
  • the absorbent articles of the present invention may also deliver a lotion or other skin health benefit agent to the wearer's skin to provide improved skin health in use when compared to conventional absorbent articles.
  • the ability of the absorbent articles of the present invention to exhibit a low level of hydration on the wearer's skin during use depends, at least in part, on the ability of the absorbent article to achieve a high rate of air exchange within the article. Moreover, it has been further discovered that the achievement of such low levels of skin hydration also depends on the ability of the article to maintain the high rate of air exchange and a more constant skin temperature even when wet.
  • the ability of an absorbent article to achieve high rates of air exchange both when dry and when wet has, for the purposes of this application, been quantified as the Dry Air Exchange Rate, the Wet Air Exchange Rate and the Wet Air Exchange Rate/Dry Air Exchange Rate ratio as determined according to the Tracer Gas Test set forth below.
  • the Tracer Gas Test involves injecting a tracer gas at a constant rate inside the absorbent article next to the skin of the wearer while the article is being worn. Simultaneously, the concentration of the tracer gas in the air space between the article and the wearer is measured by withdrawing a sample at the same constant rate as the injection. The air exchange is then determined based on mass balances of the tracer gas and the air within the space in question.
  • the absorbent articles of the different aspects of the present invention may be constructed to define a Wet Air Exchange Rate of at least about 190 cubic centimeters per minute, generally at least about 200 cubic centimeters per minute, desirably at least about 225 cubic centimeters per minute, more desirably at least about 250 cubic centimeters per minute, and even more desirably at least about 300 cubic centimeters per minute.
  • the absorbent articles may define a Wet Air Exchange Rate of from about 175 to about 1500 cubic centimeters per minute and desirably from about 225 to about 1500 cubic centimeters per minute.
  • Absorbent articles which exhibit Wet Air Exchange Rates less than those above do not allow a sufficient amount of air exchange and undesirably result in increased levels of skin hydration.
  • Such increased levels of skin hydration can render the skin more susceptible to the viability of microorganisms which can undesirably lead to an increase in the incidence of skin irritation and rash.
  • the absorbent articles of the different aspects of the present invention may further be constructed to define a Dry Air Exchange Rate of at least about 525 cubic centimeters per minute, generally at least about 575 cubic centimeters per minute, desirably at least about
  • the absorbent articles may define a Dry Air Exchange Rate of from about 525 to about 2500 cubic centimeters per minute and desirably from about 575 to about 2500 cubic centimeters per minute.
  • Absorbent articles which exhibit Dry Air Exchange Rates less than those above do not allow a sufficient amount of air exchange and undesirably result in increased levels of skin hydration. Such increased levels of skin hydration can render the skin more susceptible to the growth of microorganisms which can undesirably lead to an increase in the incidence of skin irritation and rash.
  • the absorbent articles of the different aspects of the present invention may further be constructed to define a Wet Air Exchange Rate/Dry Air Exchange Rate ratio of at least about 0.20, generally at least about 0.23, desirably at least about 0.27, and more desirably at least about 0.30 for improved performance.
  • the absorbent articles may define a Wet Air Exchange Rate/Dry Air Exchange Rate ratio of from about 0.20 to about 1 and desirably from about 0.23 to about 1 for improved performance.
  • the Skin Temperature Test involves placing the article to be tested about the forearms of test participants and measuring the temperature of the skin underneath the article before and after the article is wetted with a known amount of saline solution. The Dry Skin Temperature is recorded after the dry article has been worn for five (5) minutes. The article is then wetted and the Wet Skin Temperature is recorded after the wetted article has been worn for one hundred twenty (120) minutes.
  • the absorbent articles of the different aspects of the present invention may be constructed to define Wet Skin Temperature/Dry Skin Temperature ratio of no more than about 1.010, generally no more than about 1.005, desirably no more than about 1.000, more desirably no more than about 0.995, and even more desirably no more than about 0.990 for improved performance.
  • the absorbent articles may define a Wet Skin Temperature/Dry Skin Temperature ratio of from about 0.950 to about 1.010 and desirably from about 0.970 to about 1.005 for improved performance.
  • Absorbent articles which exhibit Wet Skin Temperature/Dry Skin Temperature ratios greater than those above do not maintain skin temperature when wet which can render the skin more susceptible to the viability of microorganisms which can undesirably lead to an increase in the incidence of skin irritation and rash.
  • the ability of the absorbent articles of the present invention to exhibit more constant skin temperature and high levels of air exchange rate both when dry and when wet has led to reduced levels of skin hydration.
  • the ability of an absorbent article to achieve a low level of skin hydration has, for the purposes of this application, been quantified as the Skin Hydration Value.
  • Skin Hydration Value refers to the value determined according to the Skin Hydration Test set forth below. In general, the Skin Hydration Value
  • Hydration Value is determined by measuring the evaporative water loss on the skin of test subjects after wearing the wetted absorbent article for a set period of time.
  • the absorbent articles of the different aspects of the present invention may be constructed to define a Skin Hydration Value of less than about 18 grams per square meter per hour, generally less than about 15 grams per square meter per hour, desirably less than about 12 grams per square meter per hour, more desirably less than about 10 grams per square meter per hour, even more desirably less than about 8 grams per square meter per hour, and yet even more desirably less than about 5 grams per square meter per hour for improved performance.
  • the absorbent articles of the present invention may define a Skin Hydration Value of from about 0.1 to about 18 grams per square meter per hour and desirably from about 0.1 to about 12 grams per square meter per hour.
  • Absorbent articles which exhibit Skin Hydration Values greater than those above can render the skin more susceptible to the growth of microorganisms which can undesirably lead to an increase in the incidence of skin irritation and rash.
  • the absorbent articles of the present invention may further exhibit reduced viability rates of microorganisms which can lead to a reduction in skin irritation. It is hypothesized that the reduced viability of microorganisms is a direct result of the increased breathability and air exchange within the articles of the present invention.
  • the ability of an absorbent article to achieve a low rate of viability of microorganisms has, for the purposes of this application, been quantified as the C. albicans viability value since it is hypothesized that the presence of Candida albicans is directly related to the incidence of irritation and, in particular, rash.
  • the term "C. albicans viability" refers to the value determined according to the Candida albicans Viability Test set forth below.
  • the Candida albicans Viability Test in general, is a comparison of the C. albicans viability under a patch of the test absorbent article to the C. albicans viability under a control patch from a conventional absorbent article having a nonbreathable outer cover, i.e. an outer cover having a WVTR of less than 100 grams per square meter per 24 hours.
  • the absorbent articles of the different aspects of the present invention may be constructed to define a C. albicans viability of less than about
  • the absorbent articles of the present invention may define a C. albicans viability of less than about 2.5, desirably less than about 2.0, and more desirably less than about 1.75 log of C. albicans colony forming units when inoculated with a suspension of about 5-7 log of C. albicans colony forming units according to the Candida albicans Viability Test.
  • Absorbent articles which exhibit C. albicans viability values greater than those above can undesirably lead to an increase in the incidence of skin irritation and rash.
  • the above C. albicans viability values are obtained without the incorporation of antimicrobial agents into the absorbent articles which can be perceived by consumers in a negative manner.
  • a given level of acceptable, improved performance may be achieved by employing an absorbent article which exhibits a Dry Air Exchange Rate of at least about 525 cubic centimeters per minute and a Wet Air Exchange Rate of at least about 175 cubic centimeters per minute, and desirably a Dry Air Exchange Rate of at least about 675 cubic centimeters per minute and a Wet Air Exchange Rate of at least about 200 cubic centimeters per minute.
  • improved performance can be achieved by employing an absorbent article which exhibits a Wet Air Exchange Rate of at least about 175 cubic centimeters per minute and a Skin Hydration Value of less than about 18 grams per square meter per hour, and desirably a Wet Air Exchange Rate of at least about 200 cubic centimeters per minute and a Skin Hydration Value of less than about 12 grams per square meter per hour.
  • absorbent articles having a Dry Air Exchange Rate of at least about 525 cubic centimeters per minute and a Wet Air Exchange Rate/Dry Air Exchange Rate ratio of at least about 0.20 and desirably a Dry Air Exchange Rate of at least about 625 cubic centimeters per minute and a Wet Air Exchange Rate/Dry Air Exchange Rate ratio of at least about 0.23.
  • Figure 1 is a representative plan view of an integral absorbent garment article, such as disposable diaper 10, of the present invention in its flat-out, uncontracted state (i.e., with all elastic induced gathering and contraction removed). Portions of the structure are partially cut away to more clearly show the interior construction of diaper 10, and the surface of the diaper which contacts the wearer is facing the viewer.
  • Fig. 2 representatively shows a sectional view of the absorbent article of Fig. 1 taken along line 2-2.
  • the disposable diaper 10 generally defines a front waist section 12, a rear waist section 14, and an intermediate section 16 which interconnects the front and rear waist sections.
  • the front and rear waist sections include the general portions of the article which are constructed to extend substantially over the wearer's front and rear abdominal 5 regions, respectively, during use.
  • the intermediate section of the article includes the general portion of the article which is constructed to extend through the wearer's crotch region between the legs.
  • the absorbent article includes a vapor permeable backsheet 20, a liquid permeable o topsheet 22 positioned in facing relation with the backsheet 20, and an absorbent body 24, such as an absorbent pad, which is located between the backsheet 20 and the topsheet 22.
  • the backsheet 20 defines a length and a width which, in the illustrated embodiment, coincide with the length and width of the diaper 10.
  • the absorbent body 24 generally defines a length and width which are less than the length and width of the s backsheet 20, respectively. Thus , marginal portions of the diaper 10, such as marginal sections of the backsheet 20, may extend past the terminal edges of the absorbent body 24.
  • the backsheet 20 extends outwardly beyond the terminal marginal edges of the absorbent body 24 to form side margins and end margins of the diaper 10.
  • the topsheet 22 is generally coextensive with the o backsheet 20 but may optionally cover an area which is larger or smaller than the area of the backsheet 20, as desired.
  • the backsheet 20 and topsheet 22 are intended to face the garment and body of the wearer, respectively, while in use.
  • the permeability of the backsheet is configured to enhance the breathability of the 5 absorbent article to reduce the hydration of the wearer's skin during use without allowing excessive condensation of vapor, such as urine, on the garment facing surface of the backsheet 20 which can undesirably dampen the wearer's clothes.
  • the diaper side margins and end margins may be elasticized with suitable elastic members, such as single or multiple strands of elastic.
  • the elastic strands may be composed of natural or synthetic rubber and may optionally be heat shrinkable or heat elasticizable.
  • the diaper 10 may include leg elastics 26 which are constructed to operably gather and shirr the side 5 margins of the diaper 10 to provide elasticized leg bands which can closely fit around the legs of the wearer to reduce leakage and provide improved comfort and appearance.
  • waist elastics 28 can be employed to elasticize the end margins of the diaper 10 to provide elasticized waists.
  • the waist elastics are configured to operably gather and shirr the waist sections to provide a resilient, comfortably close fit around the waist of the wearer.
  • the elastic members are illustrated in their uncontracted, stretched condition for the purpose of clarity.
  • Fastening means such as hook and loop fasteners 30, are employed to secure the diaper on a wearer.
  • other fastening means such as buttons, pins, snaps, adhesive tape fasteners, cohesives, mushroom-and-loop fasteners, or the like, may be employed.
  • the diaper 10 may further include other layers between the absorbent body 24 and the topsheet 22 or backsheet 20.
  • the diaper 10 may include a ventilation layer 32 located between the absorbent body 24 and the backsheet 20 to insulate the backsheet 20 from the absorbent body 24 to improve air circulation and effectively reduce the dampness of the garment facing surface of the backsheet 20.
  • the ventilation layer 32 may also assist in distributing fluid exudates to portions of the absorbent body 24 which do not directly receive the insult.
  • the diaper 10 may also include a surge management layer 34 located between the topsheet 22 and the absorbent body 24 to prevent pooling of the fluid exudates and further improve air exchange and distribution of the fluid exudates within the diaper 10.
  • the diaper 10 may be of various suitable shapes.
  • the diaper may have an overall rectangular shape, T-shape or an approximately hour-glass shape.
  • the diaper 10 has a generally l-shape.
  • the diaper 10 further defines a longitudinal direction 36 and a lateral direction 38.
  • Other suitable diaper components which may be incorporated on absorbent articles of the present invention include containment flaps, waist flaps, elastomeric side panels, and the like which are generally known to those skilled in the art.
  • diaper configurations suitable for use in connection with the instant application which may include other diaper components suitable for use on diapers are described in U.S. Patent 4,798,603 issued January 17, 1989, to Meyer et al.; U.S. 5,176,668 issued January 5, 1993, to Behapn; U.S. 5,176,672 issued January 5, 1993, to Bruemmer et al.; U.S. 5,192,606 issued March 9, 1993, to Proxmire et al., and U.S. 5,509,915 issued April 23, 1996 to Hanson et al., the disclosures of which are herein incorporated by reference.
  • the various components of the diaper 10 are integrally assembled together employing various types of suitable attachment means, such as adhesive, sonic bonds, thermal bonds or combinations thereof.
  • suitable attachment means such as adhesive, sonic bonds, thermal bonds or combinations thereof.
  • the topsheet 22 and backsheet 20 are assembled to each other and to the absorbent body 24 with lines of adhesive, such as a hot melt, pressure-sensitive adhesive.
  • other diaper components such as the elastic members 26 and 28, fastening members 30, and ventilation and surge layers 32 and 34 may be assembled into the diaper article by employing the above-identified attachment mechanisms.
  • the backsheet 20 of the diaper 10, as representatively illustrated in Figs. 1 and 2, is composed of a substantially vapor permeable material.
  • the backsheet 20 is generally constructed to be permeable to at least water vapor and has a water vapor transmission rate of at least about 1000 g/sq.m/24 hr., desirably at least about 1500 g/sq.m/24 hr, more desirably at least about 2000 g/sq.m/24 hr., and even more desirably at least about 3000 g/sq.m/24.
  • the backsheet 20 may define a water vapor transmission rate of from about 1000 to about 6000 g/sq.m/24 hr. Materials which have a water vapor transmission rate less than those above do not allow a sufficient amount of air exchange and undesirably result in increased levels of skin hydration.
  • the backsheet 20 is also desirably substantially liquid impermeable.
  • the backsheet may be constructed to provide a hydrohead value of at least about 60 cm, desirably at least about 80 cm, and more desirably at least about 100 cm when subjected to the Hydrostatic Pressure Test. Materials which have hydrohead values less than those above undesirably result in the strike through of liquids, such as urine, during use. Such fluid strike through can undesirably result in a damp, clammy feeling on the backsheet 20 during use.
  • the backsheet 20 may be composed of any suitable materials which either directly provide the above desired levels of liquid impermeability and air permeability or, in the alternative, materials which can be modified or treated in some manner to provide such levels.
  • the backsheet 20 may be a nonwoven fibrous web constructed to provide the required level of liquid impermeability.
  • a nonwoven web composed of spunbonded or meltblown polymer fibers may be selectively treated with a water repellent coating or laminated with a liquid impermeable, vapor permeable polymer film to provide the backsheet 20.
  • the backsheet 20 may comprise a nonwoven web composed of a plurality of randomly deposited hydrophobic thermoplastic meltblown fibers which are sufficiently bonded or otherwise connected to one another to provide a substantially vapor permeable and substantially liquid impermeable web.
  • the backsheet 20 may also comprise a vapor permeable nonwoven layer which has been partially coated or otherwise configured to provide liquid impermeability in selected areas.
  • Patent Application Serial No. 08/882,712 filed June 25, 1997, in the name of McCormack et al. and entitled "LOW GAUGE FILMS AND FILM/NONWOVEN LAMINATES", the disclosures of which are herein incorporated by reference.
  • the backsheet 20 is provided by a microporous film/nonwoven laminate material comprising a spunbond nonwoven material laminated to a microporous film.
  • the spunbond nonwoven comprises filaments of about 1.8 denier extruded from a copolymer of ethylene with about 3.5 weight percent propylene and defines a basis weight of from about 17 to about 25 grams per square meter.
  • the film comprises a cast coextruded film having calcium carbonate particles therein and defines a basis weight of about 58 grams per square meter prior to stretching. The film is preheated, stretched and annealed to form the micropores and then laminated to the spunbond nonwoven.
  • the resulting microporous film/nonwoven laminate based material has a basis weight of from about 30 to about 60 grams per square meter and a water vapor transmission rate of from about 3000 to about 6000 g/sq.m/24 hr.
  • film/nonwoven laminate materials are described in more detail in U.S. Patent Application No. 08/882,712 filed June 25, 1997, in the name of McCormack et al. and entitled "LOW GAUGE FILMS AND FILM/NONWOVEN LAMINATES ", the disclosure of which has been incorporated by reference.
  • the topsheet 22 suitably presents a bodyfacing surface which is compliant, soft feeling, and nonirritating to the wearer's skin. Further, the topsheet 22 may be less hydrophilic than the absorbent body 24, to present a relatively dry surface to the wearer, and may be sufficiently porous to be liquid permeable, permitting liquid to readily penetrate through its thickness.
  • a suitable topsheet 22 may be manufactured from a wide selection of web materials, such as porous foams, reticulated foams, apertured plastic films, natural fibers (for example, wood or cotton fibers), synthetic fibers (for example, polyester or polypropylene fibers), or a combination of natural and synthetic fibers.
  • the topsheet 22 is suitably employed to help isolate the wearer's skin from liquids held in the absorbent body 24.
  • the topsheet 22 may be composed of a meltblown or spunbonded web of polyolefin fibers.
  • the topsheet may also be a bonded-carded web composed of natural and/or synthetic fibers.
  • the topsheet may be composed of a substantially hydrophobic material, and the hydrophobic material may, optionally, be treated with a surfactant or otherwise processed to impart a desired level of wettability and hydrophilicity.
  • the topsheet 22 comprises a nonwoven, spunbond, polypropylene fabric composed of about 2.8-3.2 denier fibers formed into a web having a basis weight of about 22 grams per square meter and a density of about 0.06 gram per cubic centimeter.
  • the topsheet 22 may be surface treated with about 0.3 weight percent of a surfactant mixture which contains a mixture of AHCOVEL Base N-62 and GLUCOPON 220UP surfactant in about a 3:1 ratio based on a total weight of the surfactant mixture.
  • a surfactant mixture which contains a mixture of AHCOVEL Base N-62 and GLUCOPON 220UP surfactant in about a 3:1 ratio based on a total weight of the surfactant mixture.
  • the AHCOVEL Base N-62 is purchased from Hodgson Textile Chemicals Inc., a business having offices in Mount Holly, North Carolina, and includes a blend of hydrogenated ethoxylated castor oil and sorbitan monooleate in a 55:45 weight ratio.
  • the GLUCOPON 220UP is purchased from Henkel Corporation and includes alkyl polyglycoside.
  • the surfactant may also include additional ingredients such as aloe.
  • the surfactant may be applied by any conventional means, such as spraying, printing, brush coating, foam or the like.
  • the surfactant may be applied to the entire topsheet 22 or may be selectively applied to particular sections of the topsheet 22, such as the medial section along the longitudinal centerline of the diaper, to provide greater wettability of such sections.
  • the topsheet 22 of the absorbent article of the present invention may further include a lotion formulation on the outer bodyfacing surface thereof.
  • the lotion formulation may generally include an emollient, a wax and, optionally, a viscosity enhancer.
  • the lotion formulation may include from about 5 to about 95 weight percent of an emollient, from about 5 to about 95 weight percent of a wax, and from about 1 to about 25 weight percent of a viscosity enhancer based on a total weight of the lotion formulation.
  • the lotion formulation may include other ingredients as well.
  • emollients act as lubricants to reduce the abrasiveness of the topsheet to the skin and, upon transfer to the skin, help to maintain the soft, smooth and pliable appearance of the skin.
  • Suitable emollients which can be incorporated into the lotion formulation include oils such as petroleum based oils, vegetable based oils, mineral oils, natural or synthetic oils, silicone oils, lanolin and lanolin derivatives, kaolin and kaolin derivatives and the like and mixtures thereof; esters such as cetyl palmitate, stearyl palmitate, cetyl stearate, isopropyl laurate, isopropyl myristate, isopropyl palmitate and the like and mixtures thereof; glycerol esters; ethers such as eucalyptol, cetearyl glucoside, dimethyl isosorbicide polyglyceryl-3 cetyl ether, polyglyceryl-3 decyltetradecanol, propylene glycol my styl
  • the lotion formulation may include from about 5 to about 95 weight percent, desirably from about 20 to about 75 weight percent, and more desirably from about 40 to about 60 weight percent of the emollient.
  • Lotion formulations which include an amount of emollient greater than the recited amounts tend to have lower viscosities which undesirable leads to migration of the lotion.
  • lotion formulations which include an amount of emollient less than the recited amounts tend to provide less transfer to the wearer's skin.
  • the wax in the lotion formulations of the present invention primarily functions as an immobilizing agent for the emollient and any active ingredient.
  • the wax in the lotion formulation provides a tackiness to the lotion formulation which improves the transfer to the skin of the 5 wearer.
  • the presence of the wax also modifies the mode of transfer in that the lotion tends to fracture or flake off instead of actually rubbing off onto the skin of the wearer which can lead to improved transfer to the skin.
  • the wax may further function as an emollient, occlusive agent, moisturizer, barrier enhancer and combinations thereof.
  • Suitable waxes which can be incorporated into the lotion formulation include animal, vegetable, mineral or silicone based waxes which may be natural or synthetic such as, for example, bayberry wax, beeswax, C30 alkyl dimethicone, candelilla wax, camauba, ceresin, cetyl esters, esparto, hydrogenated cottonseed oil, hydrogenated jojoba oil, hydrogenated jojoba wax, hydrogenated microcrystalline wax, hydrogenated rice bran s wax, japan wax, jojoba butter, jojoba esters, jojoba wax, lanolin wax, microcryustalline wax, mink wax, motan acid wax, motan wax, ou cury wax, ozokerite, paraffin, PEG-6 beeswax, PEG-8 beeswax, rezowax, rice bran wax, shellac wax, spent grain wax, spermaceti wax, steryl dimethicone, synthetic beeswax, synthetic be
  • the lotion formulation may 5 include from about 5 to about 95 weight percent, desirably from about 25 to about 75 weight percent, and more desirably from about 40 to about 60 weight percent of the wax.
  • Lotion formulations which include an amount of wax less than the recited amounts tend to have lower viscosities which undesirable leads to migration of the lotion.
  • lotion formulations which include an amount of wax greater than the recited o amounts tend to provide less transfer to the wearer's skin.
  • a viscosity enhancer may be added to the lotion formulation to increase the viscosity to help stabilize the formulation on the bodyfacing surface of the topsheet 22 and thereby reduce migration and improve transfer to the skin.
  • the viscosity enhancer 5 increases the viscosity of the lotion formulation by at least about 50 percent, more desirably at least about 100 percent, even more desirably by at least about 500 percent, yet even more desirably by at least about 1000 percent, and even more desirably by at least about 5000 percent.
  • Suitable viscosity enhancers which can be incorporated into the lotion formulation include polyolefin resins, lipophilic/oil thickeners, ethylene/vinyl acetate copolymers, polyethylene, silica, talc, colloidal silicone dioxide, zinc stearate, cetyl hydroxy ethyl cellulose and other modified celluloses and the like and mixtures thereof.
  • a particularly well suited viscosity enhancer is an ethylene/vinyl acetate copolymer commercially available from E. I. Dupont De Ne Mours under the trade designation ELVAX.
  • the lotion formulation may include from about 0.1 to about 25 weight percent, desirably from about 5 to about 20 weight percent, and more desirably from about 10 to about 15 weight percent of the viscosity enhancer for reduced migration and improved transfer to the wearer's skin.
  • the lotion formulation can also include an active ingredient such as a diaper rash skin protectant.
  • Skin protectants are a drug product which protects injured or exposed skin or mucous membrane surface from harmful or annoying stimuli.
  • Suitable active ingredients, in addition to those mentioned above as suitable emollients, which can be incorporated into the lotion formulation include, but are not limited to, alantoin and its derivatives, aluminum hydroxide gel, calamine, cocoa butter, dimethicone, cod liver oil, glycerin, kaolin and its derivatives, lanolin and its derivatives, mineral oil, shark liver oil, talc, topical starch, zinc acetate, zinc carbonate, and zinc oxide and the like, and mixtures thereof.
  • the lotion formulation may include from about 0.10 to about 95 weight percent of the active ingredient depending upon the skin protectant and the amount desired to be transferred to the skin.
  • additional ingredients can be included in the lotion formulations of the present invention.
  • the classes of ingredients that may be used and their corresponding benefits include, without limitation: antifoaming agents (reduce the tendency of foaming during processing); antimicrobial actives; antifungal actives; antiseptic actives; antioxidants (product integrity); astringents - cosmetic (induce a tightening or tingling sensation on skin); astringent - drug (a drug product that checks oozing, discharge, or bleeding when applied to skin or mucous membrane and works by coagulating protein); biological additives (enhance the performance or consumer appeal of the product); colorants (impart color to the product); deodorants (reduce or eliminate unpleasant odor and protect against the formation of malodor on body surfaces); other emollients (help to maintain the soft, smooth, and pliable appearance of the skin by their ability to remain on the skin surface or in the stratum 5 corneum to act as lubricants, to reduce flaking
  • the articles having the lotion formulations of the present invention applied to there topsheet define a z-direction migration loss of no more than about 55%, desirably no more than about 50%, more desirably no more than about 45%, even more desirably no 5 more than about 40% and yet even more desirably no more than about 35% when subjected to the Z-Direction Lotion Migration Test set forth below.
  • the lotion formulation undesirably migrates into the interior and along the surface of the topsheet and at times through the topsheet into the absorbent body of the article which results in a lower reduction in abrasion and less o transfer to the skin of the wearer.
  • the articles having the lotion formulations of the present invention 5 applied to the topsheet define a cd-direction migration loss of no more than about 40%, desirably no more than about 35%, more desirably no more than about 30%, even more desirably no more than about 25% and yet even more desirably no more than about 20% when subjected to the CD-Direction Lotion Migration Test set forth below.
  • the lotion formulation undesirably migrates along the surface of the topsheet and at times through the topsheet into the absorbent body of the article which results in a lower reduction in abrasion and less transfer to the skin of the wearer.
  • the lotion formulation of the present invention may define a melting point of from about 30° C to about 100° C, desirably from about 35° C to about 80° C, and more desirably from about 40° C to about 75° C.
  • Lotion formulations which have lower melting points exhibit migration of the lotion during use and at elevated temperatures in storage which can undesirably result in reduced transfer to the skin.
  • lotion formulations which have higher melting points may require that the lotion be at a temperature above the flash point of the topsheet material which can undesirably lead to fires.
  • the lotion formulation of the present invention may further define a melt point viscosity of from about 50 to about 1000000 centipoise, desirably from about 50000 to about 800000 centipoise, and more desirably from about 100000 to about 500000 centipoise for reduced migration and improved transfer to the skin of the wearer.
  • Lotion formulations which have lower melt point viscosities exhibit migration of the lotion through the topsheet into the absorbent body of the article which can undesirably result in reduced transfer to the skin.
  • lotion formulations which have higher melt point viscosities may be so solid as to also exhibit a reduced transfer to the skin.
  • the lotion formulation of the present invention may also define a viscosity of from about 50 to about 10000 centipoise, desirably from about 100 to about 500 centipoise, and more desirably from about 150 to about 250 centipoise at a temperature of 60° C.
  • Lotion formulations which have lower viscosities at 60° C exhibit migration of the lotion through the topsheet into the absorbent body of the article which can undesirably result in reduced transfer to the skin.
  • lotion formulations which have higher viscosities at 60° C may be so solid as to also exhibit a reduced transfer to the skin.
  • the penetration hardness of the lotion formulations of this invention can be from about 5 to about 360 millimeters, more desirably from about 10 to about 200 millimeters, more desirably from about 20 to about 150 millimeters, and still more desirably from about 40 to about 100 millimeters.
  • the hardness of the lotion formulations of this invention is important for two reasons. First, the softer the formulation the more mobile the formulation will be, making the formulation more likely to migrate to the inner plies of the tissue, which is not desirable. Secondly, softer formulations tend to be more greasy/oily to the touch, which is also less desirable.
  • formulations having a needle penetration hardness of from about 200 to about 360 millimeters feel creamy to slightly greasy with less smoothness (depending on additives).
  • Formulations that have needle penetration hardness values of from about 5 to about 200 millimeters feel silky to creamy and very smooth (depending on additives).
  • the lotion formulation may be applied to the entire bodyfacing surface of the topsheet 22 or may be selectively applied to particular sections of the bodyfacing surface, such as the medial section along the longitudinal centerline of the diaper, to provide greater lubricity of such sections and to transfer such lotion to the wearer's skin.
  • the bodyfacing surface of the topsheet 22 may include multiple stripes of the lotion formulation o applied thereto.
  • the bodyfacing surface of the topsheet 22 may include from 1 to 10 stripes of lotion formulation extending along the longitudinal direction of the diaper 20. The stripes may extend the full length of the topsheet 22 or only a portion thereof. The stripes may also define a width of from about 0.2 to about 1 centimeters.
  • the lotion formulation should cover a sufficient amount of the surface area of the topsheet 22 to ensure adequate transfer to the skin and reduced abrasion between the topsheet 22 and the wearer's skin. Desirably, the lotion formulation is applied to at least about 5 percent and more desirably at least about 25 percent of the bodyfacing surface of the topsheet 22. 0
  • the lotion formulation can be applied to the topsheet at any add-on level which provides the desired transfer benefit.
  • the total add-on level of the lotion formulation can be from about 0.05 to about 100 mg/cm 2 , desirably from about 1 to about 50 mg/cm 2 and more desirably from about 10 to about 40 mg/cm 2 for improved performance.
  • the 5 add-on amount will depend upon the desired effect of the lotion on the product attributes and the specific lotion formulation.
  • the improved stability and reduced tendency to migrate of the lotion formulations of the present invention allows a lesser amount of lotion to be applied to the topsheet 22 to achieve the same benefit when compared with conventional lotion formulations.
  • the lotion formulation may be applied to the topsheet 22 in any of many well known manners.
  • a preferred method to uniformly apply the lotion formulation to the surface of the topsheet 22 is spraying or slot coating, because it is the most exact process and offers maximum control of the formulation distribution and transfer rate.
  • other o methods such as roto-gravure or flexographic printing, can be used.
  • the lotion formulation may be applied to the topsheet 22 by (a) heating the lotion formulation to a temperature above the melting point of the formulation, causing the formulation to melt, (b) uniformly applying the melted formulation to the bodyfacing surface s of the topsheet; and (c) resolidifying the deposits of the melted formulation.
  • resolidification of the deposits occurs almost instantaneously, without the need for external cooling means such as chill rolls. This can occur if the formulation is heated to a temperature only slightly above or at the melting point of the formulation.
  • external means such as chill rolls, either before or after the application of melt, can be 0 used if desired to accelerate resolidification.
  • the temperature of the melted formulation can advantageously be less than about 10° C, more desirably less than about 5° C, and still more desirably less than about 2° C above the melting point of the formulation prior to applying it to the topsheet for reduced migration.
  • the viscosity of the melted o formulation generally increases, which further enhances the tendency of the melted formulation to be retained on the surface.
  • the topsheet 22 of the absorbent article of the present invention may further include a skin treatment composition on the outer bodyfacing surface thereof for preserving and 5 restoring the natural integrity of the skin. This is achieved by depositing a skin health benefit agent from the topsheet 22 which may control the release of the agent to the surface of the skin.
  • the skin health benefit agent may act as a protectorant that is capable of maintaining the pH of the skin, inhibiting the activity of irritants to the skin, and maintaining skin hydration and lubrication.
  • Suitable skin treatment compositions are described in commonly assigned U.S. Patent Application Serial No. 60/141788 filed June 30, 1999 in the name of Tyrrell et al. (Attorney Docket No. 13,949), which is herein incorporated by reference.
  • Pancreatic digestive enzymes that are expelled by the body with feces have been implicated to induce skin inflammation (Anderson, P.H., Bucher, A. ., Saees, II, Lee, P.C., Davis, J.A., and Maibach, H.I., Faecal enzymes: in vivo skin irritation. Contact Dermatitis 1994; 30, 152-158).
  • the feces including these enzymes, contact the skin, the skin becomes irritated.
  • these enzymes as well as others found in feces and urine, can cleave stratum corneum proteins, thereby breaking down the natural protective barrier of the skin.
  • the skin becomes susceptible to irritation directly by these enzymes or indirectly by other "irritants" in the feces and urine that are now accessible to the viable tissue.
  • the lotion formulations and treatment compositions of the present invention may be designed to form a thin, tenacious, substantially continuous film over the skin to inhibit, or at least minimize, the effect of such irritants.
  • the treatment composition of the present invention includes a surfactant and a skin health benefit agent.
  • the treatment composition is prepared as an emulsion of the surfactant and skin health benefit agent, usually as an oil-in-water (o/w) emulsion.
  • emulsions examples include aqueous emulsions of a skin health benefit agent, e.g. zinc sulfate heptahydrate, and a surfactant such as AHCOVEL Base N-62. It has been found that when emulsions containing about 75 wt.% surfactant and up to about 25 wt.% skin health benefit agent at about 0.1 to 40 wt.% total solids are used, sufficient amounts of the skin health benefit agent transfer to the skin. Preferably, the emulsions will contain between about 5 to 30 wt.% solids.
  • a skin health benefit agent e.g. zinc sulfate heptahydrate
  • a surfactant such as AHCOVEL Base N-62. It has been found that when emulsions containing about 75 wt.% surfactant and up to about 25 wt.% skin health benefit agent at about 0.1 to 40 wt.% total solids are used, sufficient amounts of the skin health benefit agent
  • emulsions can either be applied onto a substrate from a high-solids bath (up to 40 wt.%) or from dilute baths ranging from 0.1 wt.% to about 20 wt.%.
  • the emulsion will be diluted to about 0.5 wt.% to about 15 wt.%.
  • the surfactants useful in the treatment compositions of the present invention are selected to provide superior fluid handling performance, skin protection and mildness to human skin.
  • suitable surfactants include ethoxylated hydrogenated fatty oils, monosaccharides, monosaccharides derivatives, polysaccharides, polysaccharide derivatives, and combinations thereof.
  • Water miscible nonionic surfactants are preferred and such surfactants are commercially available.
  • surfactants include AHCOVEL and GLUCOPON 220UP, which is an alkylpolyglycoside having 8 to 10 carbons in the alkyl chain, and may also be used as a part of the surfactant.
  • nonionic surfactants are the primary aliphatic alcohol ethoxylates, secondary aliphatic alcohol ethoxylates, alkylphenol ethoxylates and ethylene-oxide-propylene oxide condensates on primary alkanols, such as PLURAFACS and PLURONICS (available from BASF, Inc.) and condensates of ethylene oxide with sorbitan fatty acid esters such as TWEEN (also available from Uniqema).
  • the nonionic surfactants generally are the condensation products of an organic aliphatic or alkyl aromatic hydrophobic compound and hydrophilic ethylene oxide group.
  • any hydrophobic compound having a carboxy, hydroxy, amido, or amino group with a free hydrogen attached to the nitrogen can be condensed with ethylene oxide or with the polyhydration product thereof, polyethylene glycol, to form a water miscible nonionic surfactant.
  • suitable surfactants include polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan trioleate, polyoxyethylene sorbitan tristearate, and bovine lipid extract surfactant (Survanta, Ross Laboratories), a drug used to treat Acute Respiratory Distress Syndrome and Cystic Fibrosis, and enzymes such as papain or pepsin which cleave protein structures.
  • the nonionic surfactant may include the condensation products of a higher alcohol (e.g., an alkanol containing about 8, 9, 10, 1 1 , 12, 13, 14, 5, 16, 17 or 18 carbon atoms in a straight or branched chain configuration) condensed with about 5 to 30 moles of ethylene oxide.
  • a higher alcohol e.g., an alkanol containing about 8, 9, 10, 1 1 , 12, 13, 14, 5, 16, 17 or 18 carbon atoms in a straight or branched chain configuration
  • Examples include: lauryl or myhstyl alcohol condensed with about 16 moles of ethylene oxide (EO); thdecanol condensed with about 6 moles of EO; myhstyl alcohol condensed with about 10 moles of EO per mole of myhstyl alcohol; the condensation product of EO with a cut of coconut fatty alcohol containing a mixture of fatty alcohols with alkyl chains varying from 10, 11 , 12, 13 or 14 carbon atoms in length and wherein the condensate contains either about 6 moles of EO per mole of total alcohol or about 9 moles of EO per mole of alcohol; and tallow alcohol ethoxylates containing 6 EO to 11 EO per mole of alcohol.
  • EO ethylene oxide
  • thdecanol condensed with about 6 moles of EO myhstyl alcohol condensed with about 10 moles of EO per mole of myhstyl alcohol
  • Condensates of 2 to 30 moles of ethylene oxide with sorbitan mono- and 3C 10 -C 20 alkanoic acid esters having a HLB (hydrophilic/ lipophilic balance) of about 4 to 20, preferably about 8 to 15, may also be employed as the nonionic surfactant.
  • HLB hydrophilic/ lipophilic balance
  • Alkyl polysaccharides are alkyl polyglycosides having the formula SUGAR-O-R, where R is a hydrophobic group.
  • Suitable skin health benefit agents for use in the treatment compositions of the present invention include zinc compositions to reduce or prevent skin irritation and/or acute inflammatory reactions of the skin.
  • examples of such agents include zinc salt, zinc sulfate monohydrate, and the like.
  • the zinc salt will be present in the composition as an aqueous emulsion.
  • These agents are useful as astringents and enzyme inhibitors, and more particularly useful in inhibiting both fecal and urine proteases.
  • Zinc can interact with the catalytic site of the protease, in particular, the class of proteases known as serine proteases, to inhibit proteolytic activity. By inhibiting the proteolytic activity, the intent is to keep the skin from ever becoming irritated, rather than treating the skin once it has become irritated.
  • a further advantage of the skin health benefit agent of the present invention relates to lowering the pH.
  • the serine proteases e.g. trypsin and pancreatic elastase, which are present in, for example, feces and urine, are catalytically optimal at a basic pH of approximately 8.0 and 8.5, respectively.
  • the skin health benefit agent of the present invention has unexpectedly been found to lower the pH, thereby decreasing the catalytic efficiency of these proteases.
  • the skin health benefit agent is present in the treatment compositions of the present invention in the range of from about 0.01% to about 10% by weight of the treatment composition.
  • the agent will be present in the amount of about 0.25% to about 1 % by weight of the treatment composition.
  • the treatment compositions of the present invention may also include a protein that can be administered topically in a controlled manner.
  • a protein that can be administered topically in a controlled manner.
  • One such protein is sericin.
  • Sericin is one of two proteins that are part of the twin fibroin silk thread spun by Bombyx Mori, a domestic insect. Sericin acts as a protective envelope around the fibroin thread as it is spun, which is like spinning of fibers with soluble sizing agents to help form good quality fibers.
  • the sericin can be easily separated from silk protein by hydrolysis. Post-spun sericin, with its unique properties, is known to have high affinity to a number of proteins. When refined to a high molecular weight substance it is amenable to binding to the keratin of skin and hair, forming a resistant, moisturizing, and protective film on the skin/hair, imparting good barrier properties.
  • Sericin is a silk protein obtained by controlled hydrolysis of low molecular weight silk having a specific gravity of at least about 1.
  • a commercially available silk protein is available from Croda, Inc., of Parsippany, NJ, and is sold under the trade name CROSILK
  • Sorenco which is herein incorporated by reference in its entirety.
  • the silk protein derivatives may be chosen from one of several potential compositions. Included among the silk derivatives are silk fibers and hydrolysate of silk fibers.
  • the silk fibers may be used in the form of powder in preparing the emulsion or as a powder of a product obtained by washing and treating the silk fibers with an acid.
  • silk fibers are used as a product obtained by hydrolysis with an acid, alkali or enzyme, as disclosed in U.S. Patent No. 4,839,168 to Abe et al.; U.S. Patent No. 5,009,813 to Watanube et al., and U.S. Patent No. 5,069,898 to Goldberg, each incorporated herein by reference in its entirety.
  • Another silk derivative that may be employed in the composition of the present invention is protein obtained from degumming raw silk, as disclosed, for example, in U.S. Patent No. 4,839,165 to Hoppe et al., incorporated herein by reference in its entirety.
  • the principal protein obtained from the raw silk is sericin, which has an empirical formula of C 15 H 25 ⁇ 3 5 and a molecular weight of about 323.5.
  • a preferred silk derivative is a mixture of two or more individual amino acids, which naturally occur in silk.
  • the principal silk amino acids are glycine, alanine, serine and tyrosine.
  • a silk derivative for use in the emulsion composition of the present invention is a fine powder of silk fibroin in nonfibrous or particulate form, as disclosed in U.S. Patent No. 4,233,212 to Otoi et al., incorporated herein by reference in its entirety.
  • the fine powder is produced by dissolving a degummed silk material in at least one solvent selected from, for example, an aqueous cupriethylene diamine solution, an aqueous ammonia solution of cupric hydroxide, an aqueous alkaline solution of cupric hydroxide and glycerol, an aqueous lithium bromide solution, an aqueous solution of the chloride, nitrate or thiocyanate of calcium, magnesium or zinc and an aqueous sodium thiocyanate solution.
  • a solvent selected from, for example, an aqueous cupriethylene diamine solution, an aqueous ammonia solution of cupric hydroxide, an aqueous alkaline solution of cupric hydroxide and glycerol, an aqueous lithium bromide solution, an aqueous solution of the chloride, nitrate or thiocyanate of calcium, magnesium or zinc and an aqueous sodium thiocyanate solution.
  • the dialyzed aqueous silk fibroin solution having a silk fibroin concentration of from about 3 to 20% by weight, is subjected to at least one treatment for coagulating and precipitating the silk fibroin, such as, for example, by the addition of a coagulating salt, by aeration, by coagulation at the isoelect c point, by exposure to ultrasonic waves, by agitation at high shear rate and the like.
  • the resulting product is a silk fibroin gel, which may be incorporated directly into a treatment composition or the same may be dehydrated and dried into a powder and then dissolved in the treatment composition.
  • the silk material used to form the silk fibroin includes cocoons, raw silk, waste cocoons, raw silk waste, silk fabric waste and the like.
  • the silk material is degummed or freed from sericin by a conventional procedure such as, for example, by washing in warm water containing a surfactant-active agent or an enzyme, and then dried.
  • the degummed material is dissolved in the solvent and preheated to a temperature of from about 60 to 95° C, preferably of from about 70 to 85° C. Further details of the process of obtaining the silk fibroin are discussed in previously referenced U.S. Patent No. 4,233,212.
  • an additional protein may be present in the amount of about 0.1 to about 4.0% by weight.
  • This additional protein may be selected from the group consisting of hydrolyzed animal collagen protein obtained by an enzymatic hydrolysis, lexeine protein, vegetal protein and hydrolyzed wheat protein and mixtures thereof.
  • the treatment compositions of the present invention can be in the form of an oil-in-water (o/w) emulsion or after dilution with water, with the essential ingredients being water, surfactant, and/or co-surfactant.
  • the composition as prepared is an aqueous liquid formulation and since no particular mixing is required to form the o/w emulsion, the composition is easily prepared simply by combining all the ingredients in a suitable vessel or container.
  • the order of mixing the ingredients is not particularly important and generally the various ingredients can be added sequentially or all at once or in the form of aqueous emulsions of each or all of the primary surfactants and co-surfactants can be separately prepared and combined with each other. It is important to note that emulsions of, for instance, organic acid emulsions would not be acceptable for use in the present invention, since such emulsions would be a strong skin irritant and counterproductive to the intended use of the present invention.
  • the protein when present, can be added as an aqueous emulsion thereof or can be added directly. It is not necessary to use elevated temperatures in the formation step and room temperature is sufficient. However, higher temperatures of up to about 180° F (82.2° C), preferably 1 10 to 140° F (43.3 to 60° C), can also be used.
  • the treatment compositions will often be sterilized or formulated to contain one or more preservatives for incorporation into pharmaceutical, cosmetic or veterinary formulations.
  • These treatment compositions can be sterilized by conventional, well-known sterilization techniques, e.g., boiling or pasteurization, without substantially adversely affecting the biological activity of the composition.
  • the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions and as necessary to prepare compositions for convenient administration, such as those described above in connection with the description of the lotion formulation, such as pH adjusting and buffering agents, preservatives, and delivery vehicles.
  • Actual methods for preparing pharmaceutically administrable compounds will be known or apparent to those skilled in the art and are described in detail in, for example, Remington's Pharmaceutical Science, supra.
  • Perfumes, dyes and pigments can also be incorporated into the treatment compositions of the invention.
  • the peptone-copper complexes can be provided separately or may be compounded with conventional nontoxic carriers such as, for example, aloe vera gel, squalene, glycerol stearate, polyethylene glycol, cetyl alcohol, stearic acid, and propylene glycol, among others.
  • nontoxic carriers such as, for example, aloe vera gel, squalene, glycerol stearate, polyethylene glycol, cetyl alcohol, stearic acid, and propylene glycol, among others.
  • Such compositions may contain about 5-100% active ingredients, more preferably about 5-25%.
  • the treatment compositions may be administered to a wearer of the article with un- compromised skin or in situations where a subject is already suffering from damaged skin (e.g., peeling) due to ultraviolet or other irradiation or oxidative skin damage.
  • the treatment compositions incorporated onto the topsheet 22 such that they are administered in an amount sufficient to allow inhibition of further damage by topically administered irritating substances or other unknown irritating substances and are more effective than if the host were not treated. Amounts adequate to accomplish these effects are defined as a "therapeutically effective dose" and will vary according to the application.
  • the treatment compositions are employed for protecting the skin from damage.
  • the skin health benefit agents and/or silk proteins are administered to a host under conditions which protect the integrity of the skin, maintains physiological pH, skin hydration and lubrication.
  • the precise amounts again depend on the amount of protection desired and the extent and conditions under which the skin is exposed to potentially damaging conditions, such as those caused by fecal and urine proteases, or other irritating substances. They can generally range from about 0.1 mg to about 10 mg per day per square centimeter of skin. Single or multiple administrations of the compositions can be carried out daily or over a prolonged period of time.
  • the silk proteins of the invention may be administered to the skin in relatively large amounts without serious side effects, although indiscriminate use may produce irritation of the skin.
  • the compositions are administered prophylactically to inhibit oxidative or biochemical damage to the skin or to those suffering from only mild skin damage, irritation or inflammation of the skin, the dose may be adjusted to lower maintenance levels.
  • the treatment compositions providing skin protection and enhanced repair of the present invention may be incorporated onto the topsheet 22 of the articles of the present invention and be administered alone or as combination or adjunct therapy or prophylaxis.
  • the treatment compositions can be used in combination with other skin protective factors or those found to improve other aspects of protection or healing such as the lotion formulations described above. In this manner a synergistic effect may be attained that yields a clinical efficacy greater than that realized with any single factor.
  • treatment compositions described herein stimulate a spectrum of skin protective processes
  • skin can differ considerably in its properties, leading one to utilize a combination of a composition described herein and another compound or factor.
  • Factors with reported healing properties which can be included with the silk protein compositions for use in protective/healing formulations and methods of the present invention include, for example, epidermal growth factor, fibroblast growth factor, nerve growth factor, transforming growth factors, angiogenic growth factors, heparin, fibronectin, fibrin, platelet-derived growth factor, enzymatic superoxide dismutase, extracts of blood or factors from the blood, and other similar factors.
  • the treatment compositions may be added to the topsheet 22 by conventional means such as spraying, coating, dipping and the like although the use of high solids spray is advantageous in cases where drying and/or compression is desired to be minimized.
  • the amount of the treatment composition used will depend on the particular end use as well as factors such as basis weight and porosity of the substrate.
  • a unique and surprising aspect of the treatment compositions of the present invention includes their ability to be transferred from the topsheet to the skin. It has been found that when a liquid is introduced to the topsheet, the treatment composition will dissolve in the liquid, and then liquid-mediated transfer of the treatment composition to the skin occurs. In other words, the treatment composition including the skin health benefit agent dissolves off of the substrate into the liquid, which then deposits the thin, tenacious and substantially continuous film of the skin health benefit agent onto the skin.
  • Urine is an example of a liquid that can transfer the treatment composition from the topsheet 22 to the skin. As another example, the liquid generated by the body after abrasion or injury to the skin, might provide sufficient liquid-mediated transfer of the treatment composition from the topsheet.
  • the absorbent body 24 of the diaper may suitably comprise a matrix of hydrophilic fibers, such as a web of cellulosic fluff, mixed with particles of a high-absorbency material commonly known as superabsorbent material.
  • the absorbent body 24 comprises a matrix of cellulosic fluff, such as wood pulp fluff, and superabsorbent hydrogel-forming particles.
  • the wood pulp fluff may be exchanged with synthetic, polymeric, meltblown fibers or with a combination of meltblown fibers and natural fibers.
  • the superabsorbent particles may be substantially homogeneously mixed with the hydrophilic fibers or may be nonuniformly mixed.
  • the absorbent body 24 may comprise a laminate of fibrous webs and superabsorbent material or other suitable means of maintaining a superabsorbent material in a localized area.
  • the absorbent body 24 may have any of a number of shapes.
  • the absorbent core may be rectangular, l-shaped, or T-shaped. It is generally preferred that the absorbent body 24 be narrower in the intermediate section than in the front or rear waist sections of the diaper 10.
  • the absorbent body 24 may be provided by a single layer or, in the alternative, may be provided by multiple layers, all of which need not extend the entire length and width of the absorbent body 24.
  • the absorbent body 24 can be generally T-shaped with the laterally extending cross-bar of the "T" generally corresponding to the front waist section 12 of the absorbent article for improved performance, especially for male infants.
  • the absorbent body 24 across the front waist section 12 of the article has a cross-directional width of about 18 centimeters
  • the narrowest portion of the intermediate section 16 has a width of about 7.5 centimeters
  • in the rear waist section 14 has a width of about 11.4 centimeters.
  • the size and the absorbent capacity of absorbent body 24 should be compatible with the size of the intended wearer and the liquid loading imparted by the intended use of the absorbent article. Further, the size and the absorbent capacity of the absorbent body 24 can be varied to accommodate wearers ranging from infants through adults. In addition, it has been found that with the present invention, the densities and/or basis weights of the absorbent body 24 can be varied. In a particular aspect of the invention, the absorbent body 24 has an absorbent capacity of at least about 300 grams of synthetic urine.
  • the hydrophilic fibers and high-absorbency particles can form an average basis weight for the absorbent body 24 which is within the range of about 400-900 grams per square meter.
  • the average composite basis weight of such an absorbent body 24 is within the range of about 500-800 grams per square meter, and preferably is within the range of about 550-750 grams per square meter to provide the desired performance.
  • the absorbent body 24 can be configured with a bulk thickness which is not more than about 0.6 centimeters.
  • the bulk thickness is not more than about 0.53 centimeters, and more preferably is not more than about 0.5 centimeters to provide improved benefits.
  • the bulk thickness is determined under a restraining pressure of 0.2 psi (1.38 kPa).
  • the high-absorbency material can be selected from natural, synthetic, and modified natural polymers and materials.
  • the high-absorbency materials can be inorganic materials, such as silica gels, or organic compounds, such as crosslinked polymers.
  • crosslinked refers to any means for effectively rendering normally water-soluble materials substantially water insoluble but swellable. Such means can include, for example, physical entanglement, crystalline domains, covalent bonds, ionic complexes and associations, hydrophilic associations such as hydrogen bonding, and hydrophobic associations or Van der Waals forces.
  • Examples of synthetic, polymeric, high-absorbency materials include the alkali metal and ammonium salts of poly(acrylic acid) and poly(methacrylic acid), poly(acrylamides), poly(vinyl ethers), maleic anhydride copolymers with vinyl ethers and alpha-olefins, poly(vinyl pyrrolidone), poly(vinyl morpholinone), poly(vinyl alcohol), and mixtures and copolymers thereof.
  • Further polymers suitable for use in the absorbent core include natural and modified natural polymers, such as hydrolyzed acrylonitrile-grafted starch, acrylic acid grafted starch, methyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, and the natural gums, such as alginates, xanthum gum, locust bean gum, and the like. Mixtures of natural and wholly or partially synthetic absorbent polymers can also be useful in the present invention.
  • the high absorbency material may be in any of a wide variety of geometric forms. As a general rule, it is preferred that the high absorbency material be in the form of discrete particles. However, the high absorbency material may also be in the form of fibers, flakes, rods, spheres, needles, or the like.
  • the high absorbency material is present in the absorbent body in an amount of from about 5 to about 90 weight percent, desirably in an amount of at least about 30 weight percent, and even more desirably in an amount of at least about 50 weight percent based on a total weight of the absorbent body 24.
  • the absorbent body 24 may comprise a laminate which includes at least about 50 weight percent and desirably at least about 70 weight percent of high-absorbency material overwrapped by a fibrous web or other suitable means of maintaining the high-absorbency material in a localized area.
  • high-absorbency material suitable for use in the present invention is SANWET IM 3900 polymer available from Hoechst Celanese, a business having offices in Portsmouth, Virginia.
  • suitable superabsorbents may include FAVOR SXM 880 polymer obtained from Stockhausen, a business having offices in Greensboro, North Carolina.
  • tissue wrapsheet (not illustrated) may be employed to help maintain the integrity of the structure of the absorbent body 24.
  • the tissue wrapsheet is typically placed about the absorbent body over at least the two major facing surfaces thereof and composed of an absorbent cellulosic material, such as creped wadding or a high wet-strength tissue.
  • the tissue wrap can be configured to provide a wicking layer which helps to rapidly distribute liquid over the mass of absorbent fibers comprising the absorbent body.
  • the absorbent body 24 of the different aspects of the present invention further includes a plurality of zones of high air permeability which allow air and vapors to readily pass through the absorbent body 24 and through the vapor permeable backsheet 20 out of the diaper 10 into ambient air.
  • the absorbent body 24 may include a plurality of air passageways 40 which provide the absorbent body 24 with the zones or regions of high air permeability 42.
  • the portions of the absorbent body 24 adjacent the air passageways 40 provide zones or regions of high absorption 44.
  • the zones of high air permeability 42 are designed to provide the maximum air exchange from the absorbent body 24 while the zones of high absorption 44 are designed to receive and hold the majority of the body exudates.
  • the absorbent body 24 may define any number of zones of high air permeability 42 which provides the improved air exchange. Desirably, the absorbent body 24 defines at least 3 and more desirably at least 5 different zones of high air permeability 42 for improved performance.
  • the zones of high air permeability 42 are configured to enhance the breathability of the article to reduce the hydration of the wearer's skin during use without allowing excessive condensation of vapor, such as urine, on the garment facing surface of the backsheet 20. Such condensation of vapor on the outer surface of the diaper 10 can undesirably dampen the wearer's clothes.
  • the zones of high air permeability 42 are generally located in the area of the diaper over which air and vapor can transfer from the topsheet 22, through the absorbent body 24 and any other intervening layer or layers of material, and out the vapor permeable backsheet 20.
  • the zones of high air permeability 42 may be located throughout the entire absorbent body 24 or may be selectively located in those regions of the absorbent body 24 which provide the maximum air exchange, such as the intermediate section 16 of the diaper 20.
  • the zones of high air permeability 42 are located in the front and intermediate sections 12 and 16, respectively, of the diaper 10 for improved air exchange.
  • the zones of high absorption 44 are not designed to transfer a high level of air and vapor from the interior of the diaper.
  • the air exchange from the topsheet 22 of the diaper 10 to the backsheet 20 of the diaper and into the ambient atmosphere (exterior of the diaper) occurs generally through the absorbent body 24 in the zones of high air permeability 42.
  • Some air exchange through the absorbent body 24 can also occur in the zones of high absorption 44 to a limited degree.
  • the zones of high air permeability may have any desired configuration including rectangular, circular, hourglass, oval, and the like, and may also include selected longitudinal or lateral strips or multiple regions which may be intermittently located.
  • the zones of high air permeability 42 are provided by a plurality of air passageways 40 or apertures through the absorbent body 24 which have a generally circular configuration, in such a configuration, the zones of high absorption 44 comprise the non-apertured portions of the absorbent body 24 between the air passageways 40.
  • the zones of high air permeability 42 may have any desired dimensions which effectively provide improved air exchange while preventing excessive condensation of vapor from the absorbent body 24 through and onto the garment facing surface of the backsheet 20.
  • the zones of high air permeability 42 may define a total area of from about 5 to about 75 percent, more desirably at least about 10 percent, even more desirably from about 10 to about 70 percent, and still more desirably from about 10 to about 60 percent of the total surface area of the absorbent body 24 of the diaper 10.
  • the zones of high air permeability 42 may define a total area of from about 6 to about 90 square centimeters.
  • the diaper 10 When the total area of the zones of high air permeability 42 is greater than the above amounts, the diaper 10 may exhibit an undesirable amount of condensation of vapor on the exposed, garment facing surface of the backsheet 20 undesirably resulting in a clammy feeling on the outer surface of the diaper. Whereas, when the total area of the zones of high air permeability 42 is less than the above amounts, the diaper 10 may exhibit a low level of air exchange resulting in high levels of skin hydration which can undesirably lead to skin irritation and rash.
  • the zones of high air permeability 42 of the absorbent body 24 of the diaper 10, as representatively illustrated in Figs. 1 and 2, are constructed to be substantially permeable to at least air and preferably permeable to water vapor.
  • the zones of high air permeability 42 of the absorbent body 24 define a Frazier Porosity value which is at least about 10 percent, more desirably at least about 20 percent and even more desirably at least about 50 percent greater than the Frazier Porosity value of the zones of high absorption 44 of the absorbent body 24.
  • the term "Frazier Porosity" refers to the value determined according to the Frazier Porosity Test set forth below.
  • the zones of high air permeability may be provided in a variety of ways.
  • the zones of high air permeability 42 may be integral portions of the absorbent body 24 of the absorbent article or may be provided by apertures, holes or open spaces in the absorbent body 24.
  • portions of the absorbent body 24 may be discontinuous or removed to provide the zones 42.
  • the zones of high air permeability 42 may be provided by portions of the absorbent body 24 which are constructed to absorb less fluid exudates thereby resulting in improved air flow through such portions in use.
  • portions of the absorbent body 24 may be void of or contain substantially less 5 high-absorbency material than other portions of the absorbent body 24 to provide such improved air flow.
  • Portions of the absorbent body 24 may otherwise be treated or coated with a solution which renders them hydrophobic to provide the zones of high air permeability 42 in selected areas.
  • the zones of high air permeability 42 may be provided by creating voids or holes in the absorbent body 24 and o placing other materials having a higher air permeability than the absorbent body 24, such as those materials described below as being suitable for the surge management layer 34, in the holes or voids.
  • Figs. 1-6 Examples of several configurations of the absorbent body 24 according to different s aspects of the present invention are representatively illustrated in Figs. 1-6.
  • the zones of high air permeability 42 in the absorbent body 24 are provided by a plurality of air passageways 40 or apertures through the absorbent body 24.
  • the air passageways 40 are intermittently positioned along the entire length and width of the absorbent body 24.
  • the illustrated air passageways 40 o are circular and define a diameter of about 1.27 centimeters and a total open area of about 12 percent of a total surface area of the absorbent body 24.
  • the absorbent body 24 is in the form of discrete segments 46 which are spaced apart along the longitudinal direction 36 of the diaper 10. In such a configuration, 5 the zones of high air permeability 42 are provided by the spaces between the discrete segments 46 of the absorbent body 24.
  • the absorbent body 24 may include any number of segments 46 having a variety of shapes and sizes.
  • the absorbent body 24 includes four different segments 46 spaced apart in the longitudinal direction 36 of the diaper 10.
  • the illustrated segments 46 are generally 0 rectangular in shape and define a width which is less than a width of the absorbent body 24 which, in the illustrated embodiment, is defined by the width of the surge management layer 34 and the ventilation layer 32 as described below.
  • the segments 46 may define a width which is substantially equal to a width of the absorbent body 24.
  • the 5 segments 46 can be contained between two sheets of material such as wrapsheet (not shown) or the surge management layer 34 and the ventilation layer 32.
  • the segments 46 include a laminate of high-absorbency material between two sheets or layers of material and the zones of high air permeability 42 provided by the spaces between the segments 46 define an open area of about 40 percent of a total surface are of the absorbent body 24.
  • the zones of high air permeability 42 in the absorbent body 24 are provided by a plurality of air passageways 40 or apertures through the absorbent body 24 similar to the embodiment illustrated in Figs. 1 and 2.
  • the air passageways 40 are located in the absorbent body 24 in the front waist section 12 and the intermediate section 16 of the diaper 10 and not in the rear waist section 14.
  • the absorbent body 24 includes an upper layer 48 and a lower layer 50 with the upper layer 48 extending only along a portion of the length of the absorbent body 24.
  • the majority of the absorbent body 24 can be located in the front waist and intermediate sections 12 and 16 of the diaper 10 for improved absorption and reduced cost.
  • the illustrated air passageways 40 are circular and define a diameter of about 1.27 centimeters and a total open area of about 12 percent of a total surface area of the absorbent body 24.
  • the diaper of the different aspects of the present invention may further include a porous, liquid-permeable layer of surge management material 34, as representatively illustrated in Figs. 1 and 2.
  • the surge management layer 34 is typically less hydrophilic than the absorbent body 24, and has an operable level of density and basis weight to quickly collect and temporarily hold liquid surges, to transport the liquid from its initial entrance point and to substantially completely release the liquid to other parts of the absorbent body 24.
  • the structure of the surge management layer 34 also generally enhances the air exchange within the diaper 10.
  • the surge management layer 34 may be a layer composed of a meltblown or spunbonded web of synthetic fibers, such as polyolefin fibers.
  • the surge management layer 34 may also be a bonded-carded-web or an airlaid web composed of 5 natural and synthetic fibers.
  • the bonded-carded-web may, for example, be a thermally bonded web which is bonded using low melt binder fibers, powder or adhesive.
  • the webs can optionally include a mixture of different fibers.
  • the surge management layer 34 may be composed of a substantially hydrophobic material, and the hydrophobic material may optionally be treated with a surfactant or otherwise processed to impart a desired level of o wettability and hydrophilicity.
  • the surge management layer 34 includes a hydrophobic, nonwoven material having a basis weight of from about 30 to about 120 grams per square meter.
  • the surge management layer 34 may comprise a s bonded-carded-web, nonwoven fabric which includes bicomponent fibers and which defines an overall basis weight of about 83 grams per square meter.
  • the surge management layer 34 in such a configuration can be a homogeneous blend composed of about 60 weight percent polyethylene/polyester (PE/PET), sheath-core bicomponent fibers which have a fiber denier of about 3 d and about 40 weight percent single component o polyester fibers which have a fiber denier of about 6 d and which have fiber lengths of from about 3.8 to about 5.08 centimeters.
  • the surge management layer 34 is arranged in a direct, contacting liquid communication with the absorbent body 24.
  • the surge management 5 layer 34 may be operably connected to the topsheet 22 with a conventional pattern of adhesive, such as a swirl adhesive pattern.
  • the surge management layer 34 may be operably connected to the absorbent body 24 with a conventional pattern of adhesive.
  • the amount of adhesive add-on should be sufficient to provide the desired levels of bonding, but should be low enough to avoid excessively restricting the movement 0 of liquid from the topsheet 22, through the surge management layer 34 and into the absorbent body 24.
  • the absorbent body 24 is positioned in liquid communication with surge management layer 34 to receive liquids released from the surge management layer, and to hold and 5 store the liquid.
  • the surge management layer 34 comprises a separate layer which is positioned over another, separate layer comprising the absorbent body 24, thereby forming a dual-layer arrangement.
  • the surge management layer 34 serves to quickly collect and temporarily hold discharged liquids, to transport such liquids from the point of initial contact and spread the liquid to other parts of the surge management layer 34, and then to substantially completely release such liquids into the layer or layers comprising the absorbent body 24.
  • the surge management layer 34 can be of any desired shape. Suitable shapes include for example, circular, rectangular, triangular, trapezoidal, oblong, dog-boned, hourglass- shaped, or oval. In certain embodiments, for example, the surge management layer can be generally rectangular-shaped. In the illustrated embodiments, the surge management layer 34 is coextensive with the absorbent body 24. Alternatively, the surge management layer 34 may extend over only a part of the absorbent body 24. Where the surge management layer 34 extends only partially along the length of the absorbent body 24, the surge management layer 34 may be selectively positioned anywhere along the absorbent body 24. For example, the surge management layer 34 may function more efficiently when it is offset toward the front waist section 12 of the garment. The surge management layer 34 may also be approximately centered about the longitudinal center line of the absorbent body 24.
  • the diaper 10 may also include a ventilation layer 32 located between the backsheet 20 and the absorbent body 24.
  • the ventilation layer 32 serves to facilitate the movement of air within and through the diaper 10 and prevent the backsheet 20 from being in surface to surface contact with at least a portion of the absorbent body 24.
  • the ventilation layer 32 serves as a conduit through which air and water vapor can move from the absorbent body 24 through the vapor permeable backsheet 20.
  • the ventilation layer 32 may be formed from materials described above as being suitable for the surge management layer 34 such as nonwoven, (e.g., spunbond, meltblown or carded), woven, or knitted fibrous webs composed of natural fibers and/or synthetic polymeric fibers. Suitable fibers include, for example, acrylic fibers, polyolefin fibers, polyester fibers, or blends thereof.
  • the ventilation layer 32 may also be formed from a porous foam material such as an open-celled polyolefin foam, a reticulated polyurethane foam, and the like.
  • the ventilation layer 32 may include a single layer of material or a composite of two or more layers of material.
  • the ventilation layer 32 includes a hydrophobic, nonwoven material having a thickness of at least about 0.10 centimeters determined under a restraining pressure of 0.05 psi (0.34 kPa) and a basis weight of from about 20 to about 120 grams per square meter.
  • the ventilation layer 32 may comprise a bonded-carded-web, nonwoven fabric which includes bicomponent fibers and which defines an overall basis weight of about 83 grams per square meter.
  • the ventilation layer 32 in such a configuration can be a homogeneous blend composed of about 60 weight percent polyethylene/polyester (PE/PET), sheath-core bicomponent fibers which have a fiber denier of about 3 d and about 40 weight percent single component polyester fibers which have a fiber denier of about 6 d and which have fiber lengths of from about 3.8 to about 5.08 centimeters.
  • PE/PET polyethylene/polyester
  • sheath-core bicomponent fibers which have a fiber denier of about 3 d and about 40 weight percent single component polyester fibers which have a fiber denier of about 6 d and which have fiber lengths of from about 3.8 to about 5.08 centimeters.
  • the ventilation layer 32 can be of any desired shape. Suitable shapes include for example, circular, rectangular, triangular, trapezoidal, oblong, dog-boned, hourglass- shaped, or oval.
  • the ventilation layer 32 may extend beyond, completely over or partially over the absorbent body 24.
  • the ventilation layer 32 may suitably be located over the intermediate section 16 of the diaper 10 and be substantially centered side-to- side with respect to the longitudinal centerline 36 of the diaper 10. It is generally desired that the entire absorbent body 24 be overlaid with the ventilation layer 32 to prevent substantially all surface to surface contact between the backsheet 20 and the absorbent body 24.
  • the ventilation layer 32 is coextensive with the absorbent body 24.
  • the ventilation layer 32 is arranged in a direct, contacting liquid communication with the absorbent body 24.
  • the ventilation layer 32 may be operably connected to the backsheet 20 with a conventional pattern of adhesive, such as a swirl adhesive pattern.
  • the ventilation layer 32 may be operably connected to the absorbent body 24 with a conventional pattern of adhesive.
  • the amount of adhesive add-on should be sufficient to provide the desired levels of bonding, but should be low enough to avoid excessively restricting the movement of air and vapor from the absorbent body 24 and through the backsheet 20.
  • the ventilation layer 32 may further serve to quickly collect and temporarily hold discharged liquids, which pass through the absorbent body 24 and, in particular, through the zones of high air permeability 42 within the absorbent body 24. The ventilation layer 32 may then transport such liquids from the point of initial contact and spread the liquid to other parts of the ventilation layer 32, and then substantially completely release such liquids into the layer or layers comprising the absorbent body 24.
  • the different article embodiments of the present invention advantageously provide improved absorbent articles which exhibit substantially reduced levels of hydration of the wearer's skin when in use compared to conventional absorbent articles.
  • the reduced levels of skin hydration promote drier, more comfortable skin and render the skin less susceptible to the viability of microorganisms.
  • wearer's of absorbent articles made according to the present invention have reduced skin hydration which can lead to a reduction in the incidence of skin irritation and rash.
  • the combination of the highly breathable articles of the present invention with the lotion formulations and/or treatment compositions of the present invention can provide a synergistic reduction in the incidence of skin irritation and rash.
  • the lotion formulations and treatment compositions can provide a skin barrier and anti-inflammatory function.
  • the absorbent articles made according to the present invention can maintain or improve the health of the wearer's skin.
  • the Hydrostatic Pressure Test is a measure of the liquid barrier properties of a material. In general, the Hydrostatic Pressure Test determines the height of water (in centimeters) in a column which the material will support before a predetermined amount of water passes through. A material with a higher hydrohead value indicates it is a greater barrier to liquid penetration than a material having a lower hydrohead value.
  • the Hydrostatic Pressure Test is performed according to Method 5514 - Federal Test Methods Standard No. 191A.
  • the Frazier Porosity values referred to in the present specification can be determined employing a Frazier Air Permeability Tester (Frazier Precision Instrument Co.,
  • test is conducted with a sample which measures 8 inches x 8 inches.
  • a suitable technique for determining the WVTR (water vapor transmission rate) value of a material is as follows.
  • 3-inch diameter (76 millimeter) circular samples are cut from the test material and from a control material, Celguard ® 2500 (Hoechst Celanese Corporation). Two or three samples are prepared for each material.
  • Test cups used for testing are cast aluminum, flanged, 2 inches deep and come with a mechanical seal and neoprene gasket. The cups are distributed by Thwing-Albert Instrument Company, Philadelphia, Pennsylvania, under the designation Vapometer cup #681.
  • One hundred milliliters of distilled water are poured into each Vapometer cup, and each of the individual samples of the test materials and control material are placed across the open top area of an individual cup.
  • Screw-on flanges are tightened to form a seal along the edges of the cups leaving the associated test material or control material exposed to the ambient atmosphere over a 62 millimeter diameter circular area (an open, exposed area of about 30 cm 2 ).
  • the cups are then weighed, placed on a tray, and set in a forced air oven set at 100°F (38°C).
  • the oven is a constant temperature oven with external air circulating through it to prevent water vapor accumulation inside.
  • a suitable forced air oven is, for example, a Blue M Power-O-Matic 60 oven distributed by Blue M Electric Co. of Blue Island, Illinois. After 24 hours, the cups are removed from the oven and weighed.
  • the preliminary, test WVTR value is calculated as follows:
  • Test WVTR [(grams weight loss over 24 hours) x 7571] (g/m /24 hours)
  • the relative humidity within the oven is not specifically controlled. Under predetermined set conditions of 100°F and ambient relative humidity, the WVTR for Celguard 2500 has been determined to be 5000 g/m 2 /24 hours. Accordingly, Celguard 2500 is run as a control sample with each test. Celguard 2500 is a 0.0025 cm thick film composed of a microporous polypropylene.
  • Skin hydration values are determined by measuring total evaporative water loss (EL) and can be determined by employing the following test procedure.
  • test is conducted on partially toilet trained infants who have no lotions or ointments on the skin and have not been bathed within 2 hours prior to the test. Each infant tests one diaper during each test session.
  • the test diapers include a test code and a control code.
  • the test diapers (test code and control code) are randomized.
  • Each test diaper is weighed before and after use to verify the volume of liquid added into the diaper.
  • a felt tip pen is employed to mark an "X" at the target zone inside the diaper, with the "X” positioned 6.5 inches below the top front edge of the diaper and centered side-to-side.
  • the EL measurements are taken with an evaporimeter, such as an Evaporimeter EP1 instrument distributed by Servomed AB, Sweden. Each test measurement is taken over a period of two minutes with EWL values taken once per second (a total of 120 EWL values).
  • the digital output from the Evaporimeter EP1 instrument gives the rate of evaporative water loss (EWL) in g/m 2 /hr.
  • Skin hydration values (SHV) are in units of total amount of water loss per unit area measured during the two-minute sampling period and are calculated as follows.
  • a preliminary skin hydration value measurement is taken after a 15-minute "dryout" period when the infant wears only a long T-shirt or dress and is in the supine position.
  • the measurement is taken on the infant's lower abdomen, in a region corresponding to the target zone of the diaper, using the evaporimeter for the purpose of establishing the initial skin hydration value of the infant's skin at the diaper target zone. If the preliminary SHV is less than 10 g/m 2 /hour, a diaper is then placed on the infant. If the preliminary SHV is greater than 10 g/m 2 /hour, the "dryout" period is extended until a reading below 10 g/m 2 /hour is obtained.
  • a tube Prior to securing the diaper on the infant, a tube is positioned to direct a flow of liquid to hit the premarked target zone.
  • 210 milliliters of adjusted 0.9 weight percent aqueous saline is added in three insults of 70 milliliters each at a rate of 15 milliliters/second with a 45 second delay between insults.
  • the infant wears the diaper for 60 minutes after which the diaper is removed and a test measurement of skin hydration is taken on the lower abdomen corresponding to the target zone mark of the diaper. The measurement is taken over a 2-minute period. The used diaper is then weighed. Relative humidity and temperature measurements can be taken within the diaper prior to the skin hydration measurements being taken. The test procedure is then repeated the next day for each infant using the diaper type (test or control) which the infant has not yet worn. The control diaper provides a standardized basis for comparing the performance of the diaper configuration being tested and evaluated. The control diapers used in the tests performed in connection with the Examples were commercially available HUGGIES® Supreme diapers sold by Kimberly-Clark Corporation.
  • the value reported for the mean net SHV is the arithmetic mean for all infants of the post-wear skin hydration value, taken at the lower abdomen (target zone mark), minus the skin hydration value measured at the lower abdomen prior to placing the diaper on the infant (after "dryout" period).
  • a separate mean net SHV is determined for the test code diapers and the control code diapers.
  • the net skin hydration value is determined as follows:
  • N number of infants in study
  • the percent reduction in skin hydration is determined as follows:
  • the Tracer Gas Test is a measure of the rate of air exchange in garments such as absorbent articles and is a steady flow/steady state test described generally in TAPPI JOURNAL., Volume 80, No. 9, September 1997.
  • the air exchange rate values are calculated from the measured mass exchange within the garment.
  • the test involves injecting a tracer gas at a constant rate inside the article next to the outer surface of the torso of a mannequin while the article is secured about the mannequin. Simultaneously, the concentration of the tracer gas in the air space between the article and the mannequin is measured by withdrawing a sample at the same constant rate as the injection. The air exchange rate is then be determined based on mass balances of the tracer gas and the air within the space in question.
  • the Tracer Gas Test is completed as follows:
  • Step 3 height (waist to knees) 26 centimeters circumference at waist 42 centimeters circumference at hips 44 centimeters thigh circumference 22 centimeters
  • Step 4 height (waist to knees) 28 centimeters circumference at waist 48 centimeters circumference at hips 51 centimeters thigh circumference 27 centimeters
  • test area which is environmentally controlled to 20°C and 50% relative humidity.
  • C0 2 Analyzer An infrared C0 2 Analyzer such as Model 17515A commercially available from Vacu-Med Vacumetrics, 4483 McGrath Street #102, Ventura, California.
  • Rotameters - Rotameters to maintain gas flow rates such as Matheson Rotameter Model TS-35 commercially available from Specialty Gases Southeast Inc., 3496 Peachtree Parkway, Suwanee, Georgia.
  • the tracer gas includes 5% C0 2 and air and the calibration gas is 100% air.
  • Air Exchange Rate 150 cc/min * [(C ⁇ -C)/ (C- C 0 )]
  • the Dry Air Exchange Rate is the air exchange rate as determined according to the above procedure before the diaper has been subjected to any insults.
  • the Wet Air Exchange Rate is the air exchange rate determined according to the above procedure except that once the diaper is secured to the mannequin, 180 milliliters (Step 3) or 210 milliliters (Step 4) of adjusted 0.9 weight percent aqueous saline is added in three insults of 60 or 70 milliliters each at a rate of 15 milliliters/second with a 45 second delay between insults.
  • the Wet Air Exchange Rate/Dry Air Exchange Rate ratio is determined by dividing the Wet Air Exchange Rate by the Dry Air Exchange Rate for the same sample.
  • the C. albicans Viability Test is a measure of the effect of absorbent garments, such as disposable diapers, on the viability of pathogenic microorganisms and, in particular, Candida albicans.
  • the C. albicans Viability Test involves inoculating delineated sites of each volar forearm of test subjects with a known suspension of C. albicans cells, covering the sites with full thickness patch from the absorbent garment, and determining the viability after a 24 hour period.
  • a full thickness test sample patch having a length of about 5 centimeters and a width of about 5 centimeters is cut from the target zone of each product to be tested.
  • the target zone is generally that portion of the product intended to receive urine discharge from the wearer and typically includes portions of the intermediate and front waist sections of the product somewhat forward of the lateral centerline of the product.
  • the full thickness test sample patch includes the topsheet, absorbent body, backsheet and any intervening layers. Approximately 15 milliliters of a 0.9 weight percent saline solution is added to the test sample patch and allowed to soak in for 2 minutes before the samples are placed on the forearms of the test subjects.
  • test site area of about 6.15 square centimeters is marked on each of the test subject's volar forearms.
  • Approximately 0.01 milliliters of a 0.9 weight percent saline solution containing a known suspension of C. albicans cells is delivered to the test site with micropipettes and the suspension is then spread uniformly across the test site. After air drying, the test site is covered with the test sample patch which is secured in position using adhesive tape completely surrounding the sample.
  • test sample patches are removed and a quantitative culture is obtained from the test site using the detergent scrub method set forth in "A New Method For Quantitative Investigation of Cutaneous Bacteria", P. Williamson and A. M. Klingman, Journal of Investigative Dermatology, 45:498-503, 1965, the disclosure of which is hereby incorporated by reference. Briefly, a sterile glass cylinder encompassing an area of 6.15 square centimeters is centered over the test site and held firmly to the skin. One milliliter of 0.1 weight percent Triton-x-100 in 0.075M phosphate buffer having a pH of 7.9 is pipetted into the glass cylinder and the area scrubbed for one minute using a sterile
  • Teflon rod The fluid is aspirated with a sterile pipette and a second milliliter of 0.1 weight percent Triton-x-100 in 0.075M phosphate buffer having a pH of 7.9 is added to the glass cylinder. The scrub step is repeated and the two washes are pooled. Each pooled sample is diluted in ten-fold steps with of 0.05 weight percent Triton-x-100 in 0.0375M phosphate buffer having a pH of 7.9. A 0.01 milliliter aliquot of each dilution is inoculated onto Sabourands agar containing antibiotics. Duplicate cultures are prepared and incubated at room temperature for 48 hours.
  • the C. albicans viability under a patch of the test sample can then be compared to the C. albicans viability under a control patch from a conventional absorbent article having a nonbreathable outer cover, i.e. an outer cover having a WVTR of less than 100 grams per square meter per 24 hours, such as the diaper described below in connection with Comparative Example 4.
  • a conventional absorbent article having a nonbreathable outer cover i.e. an outer cover having a WVTR of less than 100 grams per square meter per 24 hours, such as the diaper described below in connection with Comparative Example 4.
  • Skin temperature values can be determined by employing the following test procedure.
  • the test is conducted on the bare forearm of adult human beings who have no lotions, powders or ointments on the skin and have no skin disorders. The subjects also have not been bathed, swam, smoked, exercised or consumed caffeine within 2 hours prior to and during the test.
  • Each subject tests two articles such as diapers during each test session.
  • the test diapers may include a test code and a control code such as the code identified in Comparative Example 6.
  • the test diapers (test code and control code) are randomized and are conventional Step 3 sized diapers, i.e. for infants weighing 16-28 pounds.
  • thermocouple probe with vinyl insulated 10-kt gold-plated disc sensor distributed by Cole-Parmer, a business having offices located in Vernon Hills, Illinois under the trade designation P-08506-80 which is attached to a Digi-Sense® Temperature/Humidity Logger distributed by Cole-Parmer, a business having office located in Vernon Hills, Illinois under the trade designation Model # 91090-00.
  • the thermocouple probe is calibrated to a pre-calibrated probe (3700-52) built into the data logger. The skin temperature measurements are taken continuously once per minute.
  • each test subject Upon arrival, each test subject is subjected to a 15 minute acclimation period in a controlled environment at 40% relative humidity and 71 ° F.
  • One temperature sensor is attached to each forearm, approximately midway between the wrist and elbow. The lead of the sensor is placed towards the elbow and the sensor is secured in place with a piece of tape such as Steri-Strip suture tape (0.25" X 1.5") commercially available from 3M on top of the sensor and another piece of tape to hold the sensor lead in place.
  • Baseline skin temperatures are recorded for a period of 5 minutes (5 minute total test time) without a diaper attached to the forearm.
  • sample diapers are then attached to respective forearms of each test subject such that the 1" X 1" target zones on the diaper are located over the temperature sensor.
  • a fluid dispenser nozzle Prior to securing the diapers on the forearms of the subject, a fluid dispenser nozzle, acclimated to room temperature, is positioned in each diaper above the temperature sensor to direct a flow of liquid to hit the premarked target zone.
  • Each diaper does not overlap at the target zone and is secured in place by fastening masking tape which fastens the upper and lower portions of the diaper together without contacting the skin of the wearer.
  • a size 3 5 elastic stockinet retainer commercially available from Glenwood, Inc. is placed over the entire diaper and forearm. Once the diapers are secured, dry diaper skin temperature is recorded for 5 minutes.
  • the diapers are then loaded with 180 milliliters of body temperature adjusted 0.9 weight o percent aqueous saline is added in three insults of 60 milliliters each at a rate of
  • the value reported for the skin temperature is the arithmetic mean for all subjects at the specific time during the testing period for each sample.
  • the Wet Skin Temperature/Dry Skin Temperature ratio is then determined by dividing the skin temperature value after 120 minutes of wearing the wetted sample (130 minute total test time) by the skin 0 temperature value after 5 minutes of wearing the dry sample (10 minute total test time).
  • This test determines the quantity of lotion which remains on the target area of the bodyfacing surface of an absorbent article after a given period of time at a given 5 temperature.
  • the purpose of the test is to compare the amount of lotion present in the target zone on articles stored at a lower temperature with that present on articles stored at a higher temperature.
  • the test simulates storage at elevated temperature conditions which may occur to such articles. For example, such articles may be stored in the trunk of a vehicle or in a warehouse in a warm climate such as in a o warehouse in Arizona in July or August.
  • the z-direction migration loss is a measure of the lotion migration after storage at 130° F when compared to the lotion migration at 73° F after a fixed period of time.
  • this test predicts the amount of lotion which will be available on the bodyfacing surface of the article for transfer to the skin when the article is used as well as how quickly it will undesirably migrate away from or along the bodyfacing 5 surface of the article in use. Specifically, the test is conducted as follows:
  • the products are removed from the controlled environment and a sample of the topsheet having a width of 3.75 inches and a length of 13 inches is removed from the center of each product.
  • the samples are then subjected to Soxhlet Extraction with Gravimetric Analysis (SEGA) as follows.
  • SEGA test apparatus such as that representatively illustrated in Fig. 8 is used.
  • the test apparatus 160 includes a reboiler 162, chloroform vapor duct 164, cold water condenser 166, holding tank 168 where the samples are placed and a chloroform recycle duct 170.
  • the components of the test apparatus are conventional glassware well known to those skilled in the art.
  • the reboiler may include a 250 ml round bottom flask and the vapor duct can include an 85 ml soxlet.
  • a sample is placed in the holding tank 168 and subjected to chloroform washing cycles for 2.5 hours.
  • 125 milliliters of liquid chloroform is placed in the reboiler.
  • the chloroform vaporizes and rises up through the vapor duct 164 into the condenser 166 having tap water therein which, in turn, causes the chloroform to liquefy and fall into the holding tank 168 with the sample.
  • the chloroform dissolves the lotion from the liner sample.
  • the recycle duct returns the chloroform/lotion mixture to the reboiler.
  • the temperature in the reboiler is controlled such that it is above the boiling point of the chloroform but below that of the lotion such that only the chloroform vaporizes to start the process over again.
  • One complete wash cycle takes approximately 15 minutes with about 75 milliliters of chloroform circulating through the liner sample in each cycle.
  • the chloroform in the evaporator is evaporated utilizing a conventional vacuum evaporator such as a rotovap commercially available under the model number Buchi 011 RE 121 for a period of 4 minutes followed by placing the lotion in an aluminum pan and heating on a hot plate with forced air circulation for an additional 30 minutes.
  • the residue (lotion) remaining for each sample is then weighed.
  • the amount of lotion 5 recovered from the products stored at 73°F is then compared to the amount of lotion recovered from the products stored at 130°F to determine the stability of the lotion formulation at high temperature.
  • the z-direction migration loss of the absorbent article is then determined as follows: 0
  • Z-direction migration loss (%) [(L 73 - L 130 )/L 73 ] x 100
  • L 73 average weight (g) of lotion recovered per sample stored at 73°F s
  • L 130 average weight (g) of lotion recovered per sample stored at 130°F
  • This test determines the quantity of lotion which remains on the specific location where it 0 is applied on the bodyfacing surface of an absorbent article after a given period of time at a given temperature.
  • the purpose of the test is to compare the amount of lotion present in the applied location on the topsheet or bodyside liner with that present on the remaining portions of the topsheet of the articles after being stored at an elevated temperature.
  • the test simulates storage at elevated temperature conditions which may 5 occur to such articles. For example, such articles may be stored in the trunk of a vehicle or in a warehouse in a warm climate such as in a warehouse in Arizona in July or August.
  • the cd-direction migration loss is a measure of the lateral lotion migration along the bodyfacing surface of the article after storage at 130° F after a fixed period of time.
  • this test predicts the amount of lotion which will be available in the desired location on the o bodyfacing surface of the article for transfer to the skin when the article is used as well as how quickly it will undesirably migrate away from or along the bodyfacing surface of the article in use.
  • test is conducted as follows: 5 1. Five (5) products having a lotion formulation applied to the topsheet in a specific pattern are obtained.
  • the products are placed in a controlled environment at a temperature of 130° F and ambient humidity for a fixed period of time such as, for example, 28 days.
  • the products are removed from the controlled environment and the topsheet on each product is removed and dissected to remove the portion of the topsheet to which the lotion was actually applied. For example, if the lotion was applied as 4 continuous lines having a width of 0.25 inches with spaces of 0.75 inches in between, the 4 strips of topsheet would be removed.
  • the residue (lotion) remaining for each group is then weighed.
  • the amount of lotion recovered from the portions of the topsheet to which the lotion was applied is then compared to the amount of lotion recovered from the remaining portions of the topsheet to determine the stability of the lotion formulation at high temperature.
  • the cd-direction migration loss of the absorbent article is then determined as follows:
  • CD-direction migration loss (%) [L sp /(L a + L sp )] x 100
  • L sp average weight (g) of lotion recovered from the portions of the topsheet to which the lotion was not applied per diaper
  • L a average weight (g) of lotion recovered from the portions of the topsheet to which the lotion was applied per diaper
  • Example 1 Disposable diapers having the same general construction as the HUGGIES® Supreme Step 3 diapers described in connection with Comparative Example 2 below were hand made and tested.
  • the diapers were substantially the same as the Supreme diapers except that the backsheet, absorbent core, surge layer and elasticized legbands of the diapers were replaced or modified and a ventilation layer was added between the backsheet and the absorbent core.
  • the backsheet included a microporous film/nonwoven laminate material comprising a spunbond nonwoven material laminated to a microporous film.
  • the spunbond nonwoven comprised filaments of about 1.8 denier extruded from a copolymer of ethylene with about 3.5 weight percent propylene and defined a basis weight of from about 20 grams per square meter.
  • the film comprised a cast coextruded film having calcium carbonate particles therein and defined a basis weight of about 58 grams per square meter prior to stretching. The film was preheated, stretched and annealed to form the micropores and then laminated to the spunbond nonwoven material.
  • the resulting microporous film/nonwoven laminate based material had a basis weight of 45 grams per square meter and a water vapor transmission rate of about 4000 grams per square meter per 24 hours.
  • film/nonwoven laminate materials are described in more detail in U.S. Patent Application No. 08/882, 712 filed June 25, 1997, in the name of McCormack et al. and entitled "LOW GAUGE FILMS AND FILM/NONWOVEN LAMINATES ", the disclosure of which has been incorporated by reference.
  • the absorbent core in the tested diapers was a dual layer absorbent having the general configuration set forth in Figs. 5 and 6 except that there were no holes or apertures through either layer of the absorbent.
  • the absorbent core included an upper layer and a lower layer with the upper layer extending from the front edge of the absorbent core to a location about two thirds of the total length of the absorbent core.
  • the absorbent core included from about 10 to about 11 grams of wood pulp fibers and from about 10 to about 11 grams of superabsorbent material and, accordingly, included about 50 weight percent wood pulp fibers and about 50 weight percent superabsorbent material.
  • the lower layer had a basis weight of about 230 grams per square meter and the upper layer had a basis weight of about 560 grams per square meter to provide a total basis weight of about 790 grams per square meter in the front section of the core and a basis weight of about 230 grams per square meter in the back section of the core.
  • the absorbent core further defined a width in the crotch section of about 6.35 centimeters.
  • the surge layer was located between the absorbent core and the topsheet and was the same material as the surge layer in the Supreme diapers described in Comparative Example 2 except that it was modified to be coextensive with the absorbent core.
  • the diapers also included a ventilation layer between the absorbent core and the backsheet of the diaper.
  • the ventilation layer was made of the same material as the surge layer and was also coextensive with the absorbent core.
  • the diapers also included an elasticized leg band assembly along about two thirds of the length of each longitudinal side edge of the diaper.
  • the assembly had six (6) strands of elastomeric material laminated to a breathable, nonwoven fabric layer.
  • the elastic strands were composed of LYCRA ® elastomer aligned along the longitudinal length of the diaper to elasticize and gather the diaper legbands.
  • Disposable diapers having the same general construction as the diapers described in connection with Example 1 were hand made and tested.
  • the diapers were substantially the same as the Example 1 diapers except that the absorbent body was modified to include a plurality of holes therethrough in the region where the upper layer overlaid the lower layer as illustrated in Figs. 5 and 6.
  • the holes had a diameter of 1.27 centimeters to provide an open area of about 12 percent based on a total surface area of the absorbent body.
  • Four samples of the diapers were subjected to the Tracer Gas Test set forth above. The results are set forth in Table 1 below.
  • Disposable diapers having the same general construction as the diapers described in connection with Example 2 were hand made and tested.
  • the diapers were substantially the same as the Example 2 diapers except that the ventilation layer between the absorbent body and the backsheet was removed.
  • Four samples of the diapers were subjected to the Tracer Gas Test set forth above. The results are set forth in Table 1 below.
  • Disposable diapers having the same general construction as the diapers described in connection with Example 2 were hand made and tested.
  • the diapers were substantially the same as the Example 2 diapers except that the holes in the absorbent body had a diameter of 2.54 centimeters which also defined an open are of about 12 percent of the total surface are of the absorbent body.
  • Four samples of the diapers were subjected to the Tracer Gas Test set forth above. The results are set forth in Table 1 below.
  • Disposable diapers having the same general construction as the diapers described in connection with Example 2 were hand made and tested.
  • the diapers were substantially the same as the Example 2 diapers except that the layered absorbent body was replaced with a non-layered absorbent body which included about 62 weight percent wood pulp fibers and about 38 weight percent superabsorbent and defined a basis weight in the front section of about 750 to about 850 grams per square meter and a basis weight in the back section of about 375 to about 425 grams per square meter.
  • Four samples of the diapers were subjected to the Tracer Gas Test set forth above. The results are set forth in Table 1 below.
  • Disposable diapers having the same general construction as the diapers described in connection with Example 2 were hand made and tested.
  • the diapers were substantially the same as the Example 2 diapers except that the dual layered absorbent core was replaced with a laminate which included about 80 weight percent superabsorbent material commercially available from Stockhausen under the trade designation FAVOR SXM 880 overwrapped by a tissue layer of cellulosic fibers having a basis weight of about 26 grams per square meter.
  • the absorbent body also included apertures therethrough having a diameter of 1.27 centimeters to provide an open area of about 12 percent of the total surface area of the absorbent body.
  • Disposable diapers having the same general construction as the diapers described in connection with Example 2 were hand made and tested.
  • the diapers were substantially the same as the Example 2 diapers except that the absorbent body was replaced with a laminate which included about 80 weight percent superabsorbent material commercially available from Stockhausen under the trade designation FAVOR SXM 880 overwrapped by a tissue layer of cellulosic fibers having a basis weight of about 26 grams per square meter.
  • the laminate was provided in four segments as representatively illustrated in
  • Figs. 3 and 4 which resulted in an open area for the absorbent body of about 40 percent of a total surface area of the absorbent body.
  • Disposable diapers having the same general construction as the diapers described in connection with Example 2 were hand made and tested.
  • the diapers were substantially the same as the Example 2 diapers except that the backsheet was modified to define a water vapor transmission rate of about 1870 grams per square meter per 24 hours.
  • Four samples of the diapers were subjected to the Tracer Gas Test set forth above. The results are set forth in Table 1 below. Comparative Example 1
  • Disposable diapers having the same general construction as the Supreme Step 3 diapers as described in connection with Example 2 were hand made and tested.
  • the diapers were substantially the same as the Example 2 diapers except that the backsheet was replaced with a 1 mil thick polyethylene film material having a water vapor transmission rate of less than 100 grams per square meter per hour.
  • Four samples of the diapers were subjected to the Tracer Gas Test set forth above. The results are set forth in Table 1 below.
  • the Supreme diapers comprised an absorbent core consisting of a mixture of wood pulp fibers and superabsorbent material surrounded by a two piece cellulosic wrapsheet having a basis weight of about 16-21 grams per square meter.
  • the absorbent core included from about 12.5 to about 13.5 grams of airlaid wood pulp fibers and from about 7.0 to about 8.5 grams of superabsorbent material.
  • the superabsorbent material was purchased from Stockhausen under the trade designation FAVOR SXM 880.
  • the superabsorbent material was homogeneously mixed with the pulp fibers to form a unitary layer having a density within the range of 0.25 to 0.35 grams per cubic centimeter.
  • the homogeneous mixture of the superabsorbent material and the wood pulp fibers was zoned along the machine direction to provide a basis weight of from about 600 to about 700 grams per square meter in the front section of the absorbent core and a basis weight of from about 300 to about 350 grams per square meter in the back section of the absorbent core.
  • the Supreme diapers further included a composite backsheet comprising a vapor- permeable barrier layer adhesively laminated to a spunbond/meltblown/spunbond laminate material (hereinafter "SMS").
  • SMS material had a basis weight of about 27 grams per square meter.
  • the vapor-permeable barrier layer consisted of a polyolefin film which had a thickness of about 0.7 mil. and a basis weight of about 19.5 grams per square meter.
  • the polyolefin film material was commercially available from Exxon Chemical Patents Incorporated, under the tradename EXXAIRE.
  • the vapor-permeable barrier layer was adhered to the SMS laminate and positioned between the absorbent core and the SMS laminate material of the backsheet.
  • the backsheet had a water vapor transmission rate of about 1500 grams per square meter per 24 hours.
  • the absorbent core was sandwiched between the backsheet and a topsheet composed of a spunbond 5 web of polypropylene fibers having a basis weight of about 17 grams per square meter.
  • a surge management layer composed of a bonded carded web was located between the topsheet and the absorbent core.
  • the surge layer included bicomponent fibers and defined an overall basis weight of about 83 grams per square meter.
  • the surge layer was a homogeneous blend composed of about 60 weight percent polyethylene/polyester o (PE/PET), sheath-core bicomponent fibers which had a fiber denier of about 3 d and about 40 weight percent single component polyester fibers which had a fiber denier of about 6 d and which have fiber lengths of from about 3.8 to about 5.08 centimeters.
  • the surge layer further defined a width of about 10.2 centimeters and a length of about 16.5 centimeters.
  • the front edge of the surge layer was located 5.1 centimeters from the front edge of the s absorbent core.
  • the Supreme diapers further included a single component elasticized waistband and waist flap assembly at each longitudinal end of the diaper.
  • the assembly had multiple strands of elastomeric material sandwiched and laminated between a polymer film layer and a o nonwoven fabric layer.
  • the polymer film was a 0.00075 inch thick film composed of a blend of a linear low density polyethylene and an ultra low density polyethylene.
  • the nonwoven fabric layer was composed of a 20 grams per square meter web of polypropylene spunbond.
  • the elastic strands were composed of about 8-16 strands of LYCRA ® elastomer aligned along the cross-direction of the diaper to elasticize and gather 5 the diaper waistbands and the internal waist flaps.
  • the Supreme diapers also included length-wise containment flaps which extend the full length of the diaper and elasticized leg bands along each longitudinal side edge of the diaper.
  • the elastic strands in the leg band and containment flaps were composed of LYCRA ® elastomer aligned along the longitudinal length of the diaper to elasticize and gather the diaper legbands and the 0 containment flaps.
  • test results from Examples 1-8 and Comparative Examples 1 and 2 indicate that diapers made according to the present invention generally have improved levels of air exchange both when dry and when wet when compared to conventional diapers.
  • Example 9 Four samples of diapers having the same general construction as the diapers described in connection with Example 2 were hand made and tested according to the Skin Hydration Test set forth above.
  • the diapers were substantially the same as the Example 2 diapers except that the diapers were similar in size to commercially available Step 4 size diapers, the absorbent body was a single layer having the same thickness throughout, and the apertures had a diameter of 2.54 centimeters.
  • the diapers defined an average Skin Hydration Value of 8.1 grams per square meter per hour. The results are also set forth in Table 2 below.
  • Example 10 Four samples of diapers having the same general construction as the diapers described in connection with Example 6 were hand made and tested according to the Skin Hydration Test set forth above.
  • the diapers were substantially the same as the Example 6 diapers except that the diapers were similar in size to commercially available Step 4 size diapers, the absorbent body defined a basis weight of about 560 grams per square meter and the apertures had a diameter of 2.54 centimeters.
  • the diapers defined an average Skin Hydration Value of 2.8 grams per square meter per hour. The results are also set forth in Table 2 below.
  • Example 11 Four samples of diapers having the same general construction as the diapers described in connection with Example 7 were hand made and tested according to the Skin Hydration Test set forth above. The diapers were substantially the same as the Example 7 diapers except that the diapers were similar in size to commercially available Step 4 size diapers. The diapers defined an average Skin Hydration Value of 1.6 grams per square meter per hour. The results are also set forth in Table 2 below.
  • Disposable diapers having the same general construction as those diapers commercially available from Kimberly-Clark Corporation under the trade designation HUGGIES® Supreme Step 4 were tested.
  • the Step 4 sized Supreme diapers were similar to the Step 3 sized Supreme diapers described above in connection with Comparative Example 2 except that the size of the materials was greater.
  • test results from Examples 9-1 1 and Comparative Example 3 indicate that diapers made according to the teachings of the present invention exhibit significantly improved Skin Hydration Values when compared to conventional diapers. Specifically, diapers made according to the present invention exhibited a 58 to 92 percent reduction in the Skin Hydration Value. While some reduction in the Skin Hydration Value was anticipated due to the increased amount of air exchange within the diapers, the magnitude of the reduction was unexpected.
  • Example 12 5 Samples of diapers having the same general construction as the diapers described in connection with Comparative Example 2 were hand made and tested. The diapers were substantially the same as the Comparative Example 2 diapers except that the backsheet was modified to define a water vapor transmission rate of about 3000 grams per square meter per 24 hours. The diapers were subjected to the C. albicans Viability Test set forth o above. The samples of Example 12 and Comparative Example 4 (control) were tested on the volar forearms of each of seven test subjects. Approximately 0.01 milliliters of a 0.9 weight percent saline solution containing a suspension of 5.71 log of C.
  • the sample diapers according to this s example defined a mean C. albicans viability of 1.96 log of C. albicans colony forming units. Accordingly, compared to the mean C. albicans viability of the control (Comparative Example 4), the diapers according to this example defined a reduction in the C. albicans viability value of 26 percent.
  • Samples of diapers having the same general construction as the diapers described in connection with Example 2 except that the backsheet defines a water vapor transmission rate of about 5000 grams per square meter per 24 hours are made.
  • the diapers are subjected to the C. albicans Viability Test set forth above.
  • the samples of Example 13 5 and Comparative Example 4 (control) are tested on the volar forearms of each of seven test subjects.
  • Approximately 0.01 milliliters of a 0.9 weight percent saline solution containing a suspension of 5.71 log of C. albicans colony forming units is delivered to the test site with micropipettes and the suspension is then spread uniformly across the test site. It is anticipated that the sample diapers according to this example would define a o mean C.
  • Samples of diapers having the same general construction as the diapers described in connection with Comparative Example 2 were hand made and tested.
  • the diapers were substantially the same as the Comparative Example 2 diapers except the backsheet was replaced with a 1.0 mil thick polyethylene film material having a water vapor transmission rate of less than 100 grams per square meter per 24 hours.
  • the diapers were subjected to the C. albicans Viability Test set forth above on the volar forearms of each of seven test subjects. Approximately 0.01 milliliters of a 0.9 weight percent saline solution containing a suspension of 5.71 log of C. albicans colony forming units was delivered to the test site with micropipettes and the suspension was then spread uniformly across the test site.
  • the sample diapers according to this example defined a mean C. albicans viability of 2.65 log of C. albicans colony forming units.
  • Example 14 Samples of diapers having the same general construction as the diapers described in connection with Example 13 were machine made and tested. In particular, the backsheet of the diapers defined a water vapor transmission rate of about 5000 grams per square meter per 24 hours. The diapers were subjected to the C. albicans Viability Test set forth above. The samples of Example 14 and Comparative Example 5 (control) were tested on the volar forearms of each of twenty test subjects. Approximately 0.01 milliliters of a 0.9 weight percent saline solution containing a suspension of 4.92 log of C. albicans colony forming units was delivered to the test site with micropipettes and the suspension was then spread uniformly across the test site. The sample diapers according to this example defined a mean C.
  • the diapers according to this example defined a reduction in the C. albicans viability value of 61 percent.
  • Comparative Example 5 Samples of diapers having the same general construction as the diapers described in connection with Comparative Example 4 were machine made and tested.
  • the backsheet of the diapers included a 1.0 mil thick polyethylene film material having a water vapor transmission rate of less than 100 grams per square meter per 24 hours.
  • the diapers were subjected to the C. albicans Viability Test set forth above on the volar forearms of each of twenty test subjects. Approximately 0.01 milliliters of a 0.9 weight percent saline solution containing a suspension of 4.92 log of C. albicans colony forming units was delivered to the test site with micropipettes and the suspension was then spread uniformly across the test site.
  • the sample diapers according to this example defined a mean C. albicans viability of 3.26 log of C. albicans colony forming units.
  • test results from Examples 12 and 14 and the expected results from Example 13 show that diapers made according to the present invention exhibit a reduced viability and incidence of microbial infection when compared to conventional absorbent diapers and the test results from Comparative Examples 4 and 5. It is clear that such reduced microbial viability is achieved by reducing the occlusion of the skin by increasing the breathability of the diaper both when dry and when wet.
  • Samples of diapers having the same general construction as the diapers described in connection with Example 2 except that the backsheet defined a water vapor transmission rate of about 5000 grams per square meter per 24 hours were made.
  • the diapers were subjected to the Skin Temperature Test set forth above.
  • the samples were tested on one of the forearms of each of eleven test subjects. The results of the test are shown in Figure 7.
  • the sample diapers according to this example defined a Wet Skin Temperature/Dry Skin Temperature ratio of 0.970.
  • Samples of diapers having the same general construction as the diapers described in connection with Comparative Example 2 were made.
  • the diapers were substantially the same as the Comparative Example 2 diapers except the backsheet was replaced with a 1.0 mil thick polyethylene film material having a water vapor transmission rate of less than 100 grams per square meter per 24 hours.
  • the diapers were subjected to the Skin Temperature Test set forth above.
  • the samples were tested on one of the forearms of each of eleven test subjects. The results of the test are shown in Figure 7.
  • the sample diapers according to this example defined a Wet Skin Temperature/Dry Skin Temperature ratio of 1.014.
  • Example 15 shows that diapers made according to the present invention are capable of maintaining a more constant, reduced skin temperature when wet when compared to conventional absorbent diapers and the test results from Comparative Example 6. It is hypothesized that the more constant, reduced skin temperature is achieved by reducing the occlusion of the skin by increasing the breathability of the diaper when wet. Moreover, as shown in Fig. 7, diapers made according to the present invention are capable of maintaining a skin temperature when wet which is substantially the same as the wearer's' undiapered skin temperature. Such a maintained skin temperature can result in improved comfort to the wearer.
  • a lotion formulation was prepared having the following composition:
  • Cetyl esters (synthetic spermaceti wax) 4.50
  • the lotion formulation was prepared by heating the petrolatum to 75° C and adding the remaining ingredients while maintaining the temperature at 75° C and mixing until all ingredients were melted and uniform.
  • the lotion formulation defined a bulk melting point of about 45° C and a melt point viscosity at 60° C of about 149 centipoise. The melt point viscosity at 45° C was beyond measuring limits.
  • the lotion formulation was applied to the topsheet of diapers substantially identical to HUGGIES® Supreme diapers commercially available from Kimberly-Clark Corporation at an add-on rate of about 0.2 grams per diaper.
  • the lotion was applied to the topsheet as a series of 4 lines down the center of the diaper. Each line of lotion had a width of 0.25 inches with a space having a width of 0.75 inches between each line.
  • the diapers were subjected to the Z-direction Lotion Migration Test whereby five diapers were stored at a temperature of 73° F for 28 days and five diapers were stored at a temperature of 130° F for 28 days. The diapers defined a z-direction migration loss of 44.3%.
  • the diapers were also subjected to the CD-direction Lotion Migration Test whereby five diapers were stored at a temperature of 73°F for 28 days and five diapers were stored at a temperature of 130° F for 28 days. The diapers defined a cd-direction migration loss of 16.7%. Comparative Example 7
  • the diapers included a lotion formulation on the topsheet which had the following composition:
  • the lotion formulations defined a bulk melting point of about 52°, a melt point viscosity at 50° C of about 10 centipoise and a melt point viscosity of about 5 centipoise at a temperature of 60°C.
  • the diapers were subjected to the Z-direction Lotion Migration Test whereby five diapers were stored at a temperature of 73°F for 28 days and five diapers were stored at a temperature of 130°F for 28 days.
  • the diapers defined a z-direction migration loss of 62%.
  • the diapers included a lotion formulation on the topsheet which had the following composition:
  • the lotion formulations defined a bulk melting point of about 52°, a melt point viscosity at 50° C of about 10 centipoise and a melt point viscosity of about 5 centipoise at a temperature of 60° C.
  • the diapers were subjected to the Z-direction Lotion Migration Test whereby five diapers were stored at a temperature of 73° F for 28 days and five diapers were stored at a temperature of 130° F for 28 days. The diapers defined a z-direction migration loss of 66%. Comparative Example 9
  • a lotion formulation was prepared having the following composition:
  • the lotion formulation was prepared by heating the petrolatum to 75° C and adding the stearyl alcohol while maintaining the temperature at 75° C and mixing until all ingredients were melted and uniform.
  • the lotion formulation defined a bulk melting point of about 52° C and a melt point viscosity at 60° C of about 5 centipoise.
  • the lotion formulation was applied to the topsheet of diapers substantially identical to HUGGIES® Supreme diapers commercially available from Kimberly-Clark Corporation at an add-on rate of about 0.2 grams per diaper.
  • the lotion was applied to the topsheet as a series of 4 lines down the center of the diaper. Each line of lotion had a width of 0.25 inches with a space having a width of 0.75 inches between each line.
  • the diapers were subjected to the Z-direction Lotion Migration Test whereby five diapers were stored at a temperature of 73° F for 28 days and five diapers were stored at a temperature of 130° F for 28 days. The diapers defined a z-direction migration loss of 91.7%.
  • the diapers were also subjected to the CD-direction Lotion Migration Test whereby five diapers were stored at a temperature of 73° F for 28 days and five diapers were stored at a temperature of 130° F for 28 days. The diapers defined a cd-direction migration loss of 48.9%.
  • the lotion formulation was substantially identical to that described in Example 6 in U.S. Patent No. 5,643,588 issued July 1 , 1997 to Roe et al.
  • the lotion formulation was prepared by heating the petrolatum to 75° C, adding the remaining ingredients while maintaining the temperature at 75° C and mixing until all ingredients were melted and uniform.
  • the lotion formulation defined a bulk melting point of about 54°C and a melt point viscosity at 60°C of about 54 centipoise.
  • the lotion formulation was applied to the topsheet of diapers substantially identical to HUGGIES® Supreme diapers commercially available from Kimberly-Clark Corporation at an add-on rate of about 0.2 grams per diaper.
  • the lotion was applied to the topsheet as a series of 4 lines down the center of the diaper. Each line of lotion had a width of 0.25 inches with a space having a width of 0.75 inches between each line.
  • the diapers were subjected to the Z-direction Lotion Migration Test whereby five diapers were stored at a temperature of 73°F for 28 days and five diapers were stored at a temperature of 130°F for 28 days. The diapers defined a z-direction migration loss of 69.6%.
  • the diapers were also subjected to the CD-direction Lotion Migration Test whereby five diapers were stored at a temperature of 73°F for 28 days and five diapers were stored at a temperature of 130°F for 28 days. The diapers defined a cd-direction migration loss of 50.0%.
  • the lotion formulations on the absorbent articles of the different aspects of the present invention migrate significantly less than conventional lotion formulations such as those of Comparative Examples 7-10 at elevated temperatures.
  • the articles of Example 16 exhibited about 50% less z-directional lotion migration and over 60% less cd-directional lotion migration compared to the diapers in Comparative Examples 7-10.
  • Such reduced level of migration at elevated temperatures results in more of the lotion remaining on the bodyfacing surface of the article which can lead to a higher percentage of the lotion transferring to the skin of the wearer to improve skin health and reduce friction.
  • the effect of the treatment compositions of the present invention to inhibit the hydrolysis of a model protein substrate by urine and a fecal extract was determined.
  • the ability of the treatment compositions to reduce a fecal extract-elicited pro-inflammatory response in EpiDermTM was measured.
  • the treatment composition applied to a material was placed on the EpiDermTM sample, both before and after application of the fecal irritant.
  • the release of a pro-inflammatory signaling molecule lnterleukin-1 alpha was compared to that of the control not containing the treatment composition.
  • Aqueous zinc salts were shown to inhibit a chemical reaction that contributes to diaper rash.
  • the proteolytic activity of fecal extract was measured using fluorescently labeled casein.
  • Inhibiting emulsions of zinc sulfate heptahydrate in water were prepared ranging from 0-1 mM.
  • the fecal extract (7.1 mg/ml in water) was diluted in water to 2 ⁇ g/ml.
  • the zinc sulfate heptahydrate (Aldrich Chemicals, WI) emulsions (20 ⁇ L) having a molecular weight of 287.5 were added to wells of a 96 white plate (Dynex, Chantilly, VA) containing 100 ⁇ L of a fecal extract and allowed to incubate for 15 minutes at room temperature.
  • the reaction was initiated with the addition of 80 ⁇ L of 12.5 ⁇ g/ml solution of a fluorescent dye-labeled casein substrate (EnzChek Protease Assay Kit (E-6639), Molecular Probes, Eugene, OR) in 20 mM Tris-HCI, pH 8.0. Reaction of the fecal extract with the casein substrate cleaves the fluorescent dye from the substrate. Relative fluorescence units (RFUs) were collected using the Fluoroskan Ascent System
  • FIG. 9 is a graph showing how the proteolytic activity of the fecal extract was reduced as the zinc sulfate heptahydrate concentration was increased.
  • Aqueous zinc salts were shown to inhibit a chemical reaction that contributes to diaper rash.
  • the proteolytic activity of infant urine was measured using fluorescently-labeled casein.
  • Inhibiting emulsions of zinc sulfate heptahydrate in water were prepared ranging s from 0-50 mM.
  • Two (2) infant urine (100 ⁇ L) samples were added to wells of a 96 white plate (Dynex) containing 80 ⁇ L of 12.5 ⁇ g/ml solution of a fluorescent dye-labeled casein substrate (EnzChek Protease Assay Kit (E-6639)) in 100 mM Tris-HCI, pH 8.0, and allowed to o incubate for 60 minutes at 37° C. After the incubation time, 20 ⁇ L of zinc sulfate heptahydrate in water, ranging from 0-50 mM was added to the wells. Reaction of the infant urine with the casein substrate cleaves the fluorescent dye from the substrate.
  • a fluorescent dye-labeled casein substrate EnzChek Protease Assay Kit (E-6639)
  • RFUs were collected using the Fluoroskan Ascent System with excitation and emission filters of 485 and 538 nm, respectively. Data were collected each minute for 60 minutes at 5 37°C and rates (RFU/min) from 30-50 minutes were calculated for each zinc concentration. Using the uninhibited wells as 100% protease activity, percent of urine proteolytic activity remaining was determined for each concentration of zinc inhibitor (Inhibited Rate/Uninhibited rate * 100).
  • Zinc sulfate heptahydrate was also shown to inhibit the reaction of fecal extract with synthetic skin.
  • the synthetic skin, EpiDermTM 201 (MatTek Corporation, Ashland, MA) contains keratinocytes that release interleukin-1 alpha (IL-1 alpha) when subjected to proteases in the fecal extract. When the IL-1 alpha was released, it diffused from the skin into the fluid below the EpiDermTM. Samples of this fluid were taken and analyzed for the presence of the IL-1 alpha. Higher levels of IL-1 alpha was indicative of greater skin irritation.
  • the fecal extract Prior to application onto the EpiDermTM, the fecal extract (10.4 ⁇ L) was pre-incubated for 30 minutes at room temperature with 250 mM zinc sulfate heptahydrate in water (2.6 ⁇ L). Water only and fecal extract only samples served as controls. After application of the samples to the EpiDermTM, 25 ⁇ L aliquots were removed from the underlying media at 8, 12, and 24 hours to test for the presence of the IL-1 alpha. The aliquots were directly added to a 1.5 mL micro-centrifuge tube containing 225 ⁇ L of filtered-sterilized 20 mM Tris-HCI, pH 8.0, 1 % BSA buffer and stored at -80° C. After all samples were collected, IL-1 alpha levels were quantified using the R&D Systems lnterleukin-1 alpha Quantikine Kit (R&D Systems, Minneapolis, MN).
  • FIG. 1 1 is a graph showing that the addition of the zinc sulfate heptahydrate (FE + zinc) reduced the amount of interleukin-1 alpha released into the underlying media relative to the application of the substrate treated with uninhibited fecal extract (FE + water). A similar reduction was shown at 8, 12, and 24 hours.
  • the asterisk over the error bars in FIG. 11 represent a Student t-test 95% confidence interval.
  • Skin treatment compositions of the present invention were formed by creating an emulsion (or microemulsion) of a skin health benefit agent and water as the carrier liquid.
  • Aqueous emulsions of zinc salt as the skin health benefit agent, AHCOVEL, as the surfactant system, and CROSILK as the silk protein, were prepared.
  • the stable emulsions were diluted to about a 5% by weight emulsion and applied to the surface of a polyolefin nonwoven topsheet fabric via a saturation dip and squeeze process as follows:
  • Untreated polypropylene spunbond materials (basis weight of about 0.5 ounces per square yard) were used as a substrate for the treatment compositions.
  • the compositions were applied to the substrates by a low-solids batch treatment process.
  • An 8 in. x 12 in. (20.32 x 30.48 cm) example of the substrate was first dipped in an aqueous treatment bath of known composition illustrated in Table 3 below.
  • %WPU wet pick-up
  • %WPU [(Ww- Wd)/Wd] ⁇ l 0 , where:
  • Ww wet weight of the nipped fabric
  • Wd dry weight of the treated fabric
  • the treated spunbond materials were tested to assess their capacity to inhibit the reaction of fecal extract with synthetic skin.
  • the fecal extract was prepared from feces obtained from an infant on antibiotics (Sulfatrim) who had diaper rash. To prepare the extract, the feces were suspended in water and vigorously vortexed. After vortexing, the samples were held on ice prior to centrifugation at 15,000 times the force of gravity for 20 minutes.
  • the synthetic skin, EpiDermTM 201 contains keratinocytes that release interleukin-1 alpha (IL-1 alpha) when subjected to proteases such as trypsin and pancreatic elastase. When the IL-1 alpha is released, it diffuses from the skin into the fluid below the EpiDermTM. Samples of this fluid are taken and analyzed for the presence of the IL-1 alpha. Higher levels of IL-1 alpha are indicative of greater skin irritation.
  • Fecal extract was prepared as described above for the examples of silk protein and zinc compositions.
  • SERICIN and CROSILK (20 ⁇ L) were added to wells of a 96 white plate (Dynex, Chantilly, VA) containing 80 ⁇ L of a 12.5 ⁇ g/ml solution of a fluorescent dye- labeled casein substrate (EnzChek Protease Assay Kit (E-6639), Molecular Probes, Eugene, OR).
  • E-6639 Molecular Probes, Eugene, OR
  • Relative fluorescence units were collected using the Fluoroskan Ascent System (Labsystems, Incorporated, Needham Heights, MA) with excitation and emission filters of 485 and 538 nm, respectively. The reaction was run for 30 min. at room temperature and rates (RFU/min) from 10-20 minutes were calculated. Percent of fecal proteolytic activity remaining was determined for each concentration of SERICN and CROSILK inhibitor (Inhibited Rate/Uninhibited rate * 100).
  • FIG. 13 is a graph showing reduction of proteolytic activity with increasing concentrations of both SERICIN and CROSILK.

Abstract

L'invention concerne un article absorbant comprenant une couche inférieure perméable aux vapeurs, une couche supérieure perméable aux liquides située face à la couche inférieure, et un corps absorbant placé entre la couche inférieure et la couche supérieure. Le corps absorbant peut comporter des zones multiples de perméabilité à l'air élevée. L'article absorbant peut également inclure une couche respirante située entre le corps absorbant et la couche inférieure, et une couche répartissant les liquides, située entre le corps absorbant et la couche supérieure. Les échanges d'air sont améliorés à l'intérieur de l'article, lors de son utilisation. En conséquence, l'article permet de maintenir la température et de diminuer sensiblement les niveaux d'hydratation cutanée chez l'utilisateur, la peau étant alors moins sensible à la viabilité des micro-organismes. L'article absorbant peut, en outre, contenir des préparations de lotions et/ou des compositions de traitement permettant de protéger ou d'améliorer la santé cutanée.
PCT/US1999/019571 1998-08-25 1999-08-25 Article absorbant protegeant et ameliorant la sante cutanee WO2000010500A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU60210/99A AU748171B2 (en) 1998-08-25 1999-08-25 Absorbent article which maintains or improves skin health
EP99967816A EP1107719A1 (fr) 1998-08-25 1999-08-25 Article absorbant protegeant et ameliorant la sante cutanee
KR1020017002351A KR20010085581A (ko) 1998-08-25 1999-08-25 피부 건강을 유지하거나 또는 개선시키는 흡수 용품
JP2000565825A JP2003526390A (ja) 1998-08-25 1999-08-25 皮膚の健康を維持または改善する吸収性物品
BR9913236-2A BR9913236A (pt) 1998-08-25 1999-08-25 Artigo absorvente que mantém ou melhora a saúde da pele

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US9781098P 1998-08-25 1998-08-25
US13982498A 1998-08-25 1998-08-25
US09/139,820 US6152906A (en) 1998-08-25 1998-08-25 Absorbent article having improved breathability
US09/139,820 1998-08-25
US60/097,810 1998-08-25
US09/139,824 1998-08-25
US09/298,314 1999-04-23
US09/298,314 US6149934A (en) 1999-04-23 1999-04-23 Absorbent article having a lotionized bodyside liner
US09/328,681 1999-06-09
US09/328,681 US6287286B1 (en) 1998-08-25 1999-06-09 Absorbent article having a reduced viability of candida albicans
US14178899P 1999-06-30 1999-06-30
US60/141,788 1999-06-30
US09/343,861 1999-06-30
US09/343,861 US6497893B1 (en) 1999-06-30 1999-06-30 Silk protein treatment composition and treated substrate for transfer to skin
US14693499P 1999-07-30 1999-07-30
US60/146,934 1999-07-30
US09/377,294 1999-08-19
US09/377,294 US6448464B1 (en) 1999-07-30 1999-08-19 Absorbent article which maintains skin temperature when wet
US09/379,431 US6217890B1 (en) 1998-08-25 1999-08-23 Absorbent article which maintains or improves skin health
US09/379,431 1999-08-23

Publications (1)

Publication Number Publication Date
WO2000010500A1 true WO2000010500A1 (fr) 2000-03-02

Family

ID=27580972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019571 WO2000010500A1 (fr) 1998-08-25 1999-08-25 Article absorbant protegeant et ameliorant la sante cutanee

Country Status (10)

Country Link
EP (1) EP1107719A1 (fr)
JP (1) JP2003526390A (fr)
KR (1) KR20010085581A (fr)
CN (1) CN1328438A (fr)
AU (1) AU748171B2 (fr)
BR (1) BR9913236A (fr)
ID (1) ID28949A (fr)
PL (1) PL348227A1 (fr)
TR (3) TR200100587T2 (fr)
WO (1) WO2000010500A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022933A1 (fr) * 1999-09-28 2001-04-05 The Procter & Gamble Company Article possedant une composition transferable, permeable a l'air destinee au soin de la peau
US6277479B1 (en) 1997-12-19 2001-08-21 Kimberly-Clark Worldwide, Inc. Microporous films having zoned breathability
WO2001083876A1 (fr) * 2000-04-27 2001-11-08 Kimberly-Clark Worldwide, Inc. Textiles non-tisses modifies au moyen de petrolatum
WO2001087588A2 (fr) * 2000-05-15 2001-11-22 Kimberly-Clark Worldwide, Inc. Stratifie elastique cible
WO2002051456A2 (fr) * 2000-12-22 2002-07-04 Kimberly-Clark Worldwide, Inc. Articles absorbants obtenus a partir de compositions non aqueuses contenant des extraits de plantes
WO2002051363A2 (fr) * 2000-12-22 2002-07-04 Kimberly-Clark Worldwide, Inc. Articles absorbants de compositions simplifiees possedant une bonne stabilite
US6433243B1 (en) 1999-02-26 2002-08-13 Kimberly-Clark Worldwide, Inc. Water permeable porous layer materials treated with surfactant-modified cyclodextrins
WO2003004070A1 (fr) * 2001-07-03 2003-01-16 The Procter & Gamble Company Compositions formant un film permettant de proteger la peau contre des fluides corporels et articles prepares a partir de cette composition
WO2003051250A1 (fr) * 2001-12-18 2003-06-26 Sca Hygiene Products Ab Article absorbant et son procede de production
US6656168B2 (en) 2001-12-18 2003-12-02 Kimberly-Clark Worldwide, Inc. Feminine care product with discrete areas of a skin wellness additive
GB2399787A (en) * 2000-05-15 2004-09-29 Kimberly Clark Co Targeted elastic laminate
US6939553B2 (en) 2000-09-11 2005-09-06 Kimberly-Clark Worldwide, Inc. Treated substrate with improved transfer efficiency of topical application
US7018945B2 (en) 2002-07-02 2006-03-28 Kimberly-Clark Worldwide, Inc. Composition and method for treating fibers and nonwoven substrates
WO2006071428A1 (fr) * 2004-12-28 2006-07-06 Kimberly-Clark Worldwide, Inc. Systeme de nettoyage de la peau comprenant une formulation anti-adherente et un compose cationique
US7179951B2 (en) 2000-06-21 2007-02-20 The Procter & Gamble Company Absorbent barrier structures having a high convective air flow rate and articles made therefrom
US7323615B2 (en) 2001-12-18 2008-01-29 Sca Hygiene Products Ab Absorbent article and method of production
EP2309969A2 (fr) * 2008-06-30 2011-04-20 Kimberly-Clark Worldwide, Inc. Produit d'administration de compositions topiques
US8748690B2 (en) 2006-11-17 2014-06-10 Sca Hygiene Products Ab Absorbent articles comprising acidic cellulosic fibers and an organic zinc salt
US8795716B2 (en) 2001-10-01 2014-08-05 The Procter & Gamble Company Skin care compositions on a thin sanitary napkin
US9035123B2 (en) 2002-10-01 2015-05-19 The Procter & Gamble Company Absorbent article having a lotioned topsheet
US9555150B2 (en) 2006-11-17 2017-01-31 Sca Hygiene Products Ab Absorbent articles comprising an organic zinc salt and an anti-bacterial agent or alkali metal chloride or alkaline earth metal chloride
WO2018004400A1 (fr) * 2016-06-27 2018-01-04 Sca Hygiene Products Ab Article absorbant comprenant une composition d'huile et une couche de protection contre l'huile
WO2023052831A1 (fr) * 2021-10-03 2023-04-06 Vaezi Shirin Short isolé pour la natation pendant les règles, la grossesse et l'état d'incontinence des personnes âgées

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062816A1 (en) * 2001-10-01 2006-03-23 Gatto Joseph A Sanitary napkins with hydrophobic lotions
CN1319499C (zh) * 2005-08-08 2007-06-06 梁亮胜 复式导流固水型卫生巾
JP4964728B2 (ja) * 2007-09-28 2012-07-04 大王製紙株式会社 使い捨ておむつ
JP2020533155A (ja) * 2017-09-21 2020-11-19 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ 吸収性物品
CN114025727B (zh) 2019-05-31 2023-04-14 宝洁公司 具有腰部衬圈元件的吸收制品
CN110946712B (zh) * 2019-12-31 2021-06-18 露乐健康科技股份有限公司 具有柔臀健脂护理功能的纸尿裤
EP4146132A1 (fr) 2020-05-05 2023-03-15 The Procter & Gamble Company Articles absorbants comprenant des panneaux élastiques améliorés

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5609587A (en) * 1995-08-03 1997-03-11 The Procter & Gamble Company Diaper having a lotioned topsheet comprising a liquid polyol polyester emollient and an immobilizing agent
GB2308814A (en) * 1994-11-23 1997-07-09 Kimberly Clark Co Diaper with humidity transfer area
WO1997036561A1 (fr) * 1996-03-29 1997-10-09 Kimberly-Clark Worldwide, Inc. Article absorbant dote d'un gradient de pouvoir respirant
WO1997045259A1 (fr) * 1996-05-29 1997-12-04 E.I. Du Pont De Nemours And Company Structure en feuille composite permeable a l'air et articles absorbants ayant cette structure
EP0813848A1 (fr) * 1996-06-17 1997-12-29 The Procter & Gamble Company Articles absorbants perméables à la vapeur d'eau, avec réduction des odeurs
EP0875233A1 (fr) * 1997-04-24 1998-11-04 Fort James Corporation Substrat traité avec une lotion
EP0887056A1 (fr) * 1997-06-25 1998-12-30 The Procter & Gamble Company Article absorbant jetable comportant un contennu d'humidité peu élevé

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560372A (en) * 1984-05-01 1985-12-24 Personal Products Company Stable disposable absorbent structure
RU2127573C1 (ru) * 1991-01-03 1999-03-20 Дзе Проктер Энд Гэмбл Компани Многослойный абсорбирующий сердечник и использующее его абсорбирующее изделие
US5306266A (en) * 1992-12-21 1994-04-26 The Procter & Gamble Company Flexible spacers for use in disposable absorbent articles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2308814A (en) * 1994-11-23 1997-07-09 Kimberly Clark Co Diaper with humidity transfer area
US5609587A (en) * 1995-08-03 1997-03-11 The Procter & Gamble Company Diaper having a lotioned topsheet comprising a liquid polyol polyester emollient and an immobilizing agent
WO1997036561A1 (fr) * 1996-03-29 1997-10-09 Kimberly-Clark Worldwide, Inc. Article absorbant dote d'un gradient de pouvoir respirant
WO1997045259A1 (fr) * 1996-05-29 1997-12-04 E.I. Du Pont De Nemours And Company Structure en feuille composite permeable a l'air et articles absorbants ayant cette structure
EP0813848A1 (fr) * 1996-06-17 1997-12-29 The Procter & Gamble Company Articles absorbants perméables à la vapeur d'eau, avec réduction des odeurs
EP0875233A1 (fr) * 1997-04-24 1998-11-04 Fort James Corporation Substrat traité avec une lotion
EP0887056A1 (fr) * 1997-06-25 1998-12-30 The Procter & Gamble Company Article absorbant jetable comportant un contennu d'humidité peu élevé

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277479B1 (en) 1997-12-19 2001-08-21 Kimberly-Clark Worldwide, Inc. Microporous films having zoned breathability
US6433243B1 (en) 1999-02-26 2002-08-13 Kimberly-Clark Worldwide, Inc. Water permeable porous layer materials treated with surfactant-modified cyclodextrins
WO2001022933A1 (fr) * 1999-09-28 2001-04-05 The Procter & Gamble Company Article possedant une composition transferable, permeable a l'air destinee au soin de la peau
WO2001083876A1 (fr) * 2000-04-27 2001-11-08 Kimberly-Clark Worldwide, Inc. Textiles non-tisses modifies au moyen de petrolatum
US6626961B1 (en) 2000-04-27 2003-09-30 Kimberly-Clark Worldwide, Inc. Nonwovens modified with petrolatum
KR100805570B1 (ko) 2000-04-27 2008-02-20 킴벌리-클라크 월드와이드, 인크. 바셀린으로 개질된 부직포
AU2001247943B2 (en) * 2000-04-27 2005-04-28 Kimberly-Clark Worldwide, Inc. Nonwovens modified with petrolatum
WO2001087588A2 (fr) * 2000-05-15 2001-11-22 Kimberly-Clark Worldwide, Inc. Stratifie elastique cible
WO2001087588A3 (fr) * 2000-05-15 2002-08-22 Kimberly Clark Co Stratifie elastique cible
GB2378920B (en) * 2000-05-15 2004-12-01 Kimberly Clark Co Targeted elastic laminate
GB2399787B (en) * 2000-05-15 2004-12-01 Kimberly Clark Co Targeted elastic laminate
GB2378920A (en) * 2000-05-15 2003-02-26 Kimberly Clark Co Targeted elastic laminate
GB2399787A (en) * 2000-05-15 2004-09-29 Kimberly Clark Co Targeted elastic laminate
US7179951B2 (en) 2000-06-21 2007-02-20 The Procter & Gamble Company Absorbent barrier structures having a high convective air flow rate and articles made therefrom
US7291763B2 (en) 2000-06-21 2007-11-06 The Procter And Gamble Company Absorbent barrier structures having a high convective air flow rate and articles made therefrom
US6939553B2 (en) 2000-09-11 2005-09-06 Kimberly-Clark Worldwide, Inc. Treated substrate with improved transfer efficiency of topical application
WO2002051363A2 (fr) * 2000-12-22 2002-07-04 Kimberly-Clark Worldwide, Inc. Articles absorbants de compositions simplifiees possedant une bonne stabilite
KR100848753B1 (ko) 2000-12-22 2008-07-25 킴벌리-클라크 월드와이드, 인크. 음이온 중합체를 함유하는 비수성 조성물을 갖는 흡수 용품
WO2002051456A2 (fr) * 2000-12-22 2002-07-04 Kimberly-Clark Worldwide, Inc. Articles absorbants obtenus a partir de compositions non aqueuses contenant des extraits de plantes
WO2002060502A3 (fr) * 2000-12-22 2003-12-24 Kimberly Clark Co Articles absorbants comprenant des compositions non aqueuses contenant des polymeres anioniques
WO2002051456A3 (fr) * 2000-12-22 2003-06-05 Kimberly Clark Co Articles absorbants obtenus a partir de compositions non aqueuses contenant des extraits de plantes
WO2002051363A3 (fr) * 2000-12-22 2003-02-06 Kimberly Clark Co Articles absorbants de compositions simplifiees possedant une bonne stabilite
WO2002060502A2 (fr) * 2000-12-22 2002-08-08 Kimberly-Clark Worldwide, Inc. Articles absorbants comprenant des compositions non aqueuses contenant des polymeres anioniques
WO2003004070A1 (fr) * 2001-07-03 2003-01-16 The Procter & Gamble Company Compositions formant un film permettant de proteger la peau contre des fluides corporels et articles prepares a partir de cette composition
US7449613B2 (en) 2001-07-03 2008-11-11 The Procter & Gamble Company Film-forming compositions for protecting skin from body fluids and articles made therefrom
KR100598199B1 (ko) * 2001-07-03 2006-07-07 더 프록터 앤드 갬블 캄파니 체액으로부터 피부를 보호하기 위한 필름 형성 조성물 및그로부터 제조된 제품
CN1294993C (zh) * 2001-07-03 2007-01-17 宝洁公司 用于保护皮肤使之免受体液侵害的成膜组合物及由其制成的制品
US8795716B2 (en) 2001-10-01 2014-08-05 The Procter & Gamble Company Skin care compositions on a thin sanitary napkin
WO2003063746A1 (fr) * 2001-12-18 2003-08-07 Sca Hygiene Products Ab Article absorbant et son procede de production
US7323615B2 (en) 2001-12-18 2008-01-29 Sca Hygiene Products Ab Absorbent article and method of production
US6656168B2 (en) 2001-12-18 2003-12-02 Kimberly-Clark Worldwide, Inc. Feminine care product with discrete areas of a skin wellness additive
AU2002349856B2 (en) * 2001-12-18 2008-04-17 Essity Hygiene And Health Aktiebolag Absorbent article and method of production of an absorbent article
WO2003051250A1 (fr) * 2001-12-18 2003-06-26 Sca Hygiene Products Ab Article absorbant et son procede de production
US7589250B2 (en) 2001-12-18 2009-09-15 Sca Hygiene Products Ab Absorbent article and method of production of an absorbent article
US7598428B2 (en) 2001-12-18 2009-10-06 Sca Hygiene Products Ab Absorbent article and method of production
US7018945B2 (en) 2002-07-02 2006-03-28 Kimberly-Clark Worldwide, Inc. Composition and method for treating fibers and nonwoven substrates
US10687991B2 (en) 2002-10-01 2020-06-23 The Procter & Gamble Company Absorbent article having a lotioned topsheet
US9737446B2 (en) 2002-10-01 2017-08-22 The Procter & Gamble Company Absorbent article having a lotioned topsheet
US9035123B2 (en) 2002-10-01 2015-05-19 The Procter & Gamble Company Absorbent article having a lotioned topsheet
WO2006071428A1 (fr) * 2004-12-28 2006-07-06 Kimberly-Clark Worldwide, Inc. Systeme de nettoyage de la peau comprenant une formulation anti-adherente et un compose cationique
AU2005322486B2 (en) * 2004-12-28 2010-10-28 Kimberly-Clark Worldwide, Inc. Skin cleansing system comprising an anti-adherent formulation and a cationic compound
US8748690B2 (en) 2006-11-17 2014-06-10 Sca Hygiene Products Ab Absorbent articles comprising acidic cellulosic fibers and an organic zinc salt
US9555150B2 (en) 2006-11-17 2017-01-31 Sca Hygiene Products Ab Absorbent articles comprising an organic zinc salt and an anti-bacterial agent or alkali metal chloride or alkaline earth metal chloride
US8603054B2 (en) 2008-06-30 2013-12-10 Kimberly-Clark Worldwide, Inc. Delivery product for topical compositions
EP2309969A4 (fr) * 2008-06-30 2011-08-03 Kimberly Clark Co Produit d'administration de compositions topiques
EP2309969A2 (fr) * 2008-06-30 2011-04-20 Kimberly-Clark Worldwide, Inc. Produit d'administration de compositions topiques
WO2018004400A1 (fr) * 2016-06-27 2018-01-04 Sca Hygiene Products Ab Article absorbant comprenant une composition d'huile et une couche de protection contre l'huile
US10932959B2 (en) 2016-06-27 2021-03-02 Essity Hygiene And Health Aktiebolag Absorbent article with an oil composition and an oil protecting layer
WO2023052831A1 (fr) * 2021-10-03 2023-04-06 Vaezi Shirin Short isolé pour la natation pendant les règles, la grossesse et l'état d'incontinence des personnes âgées

Also Published As

Publication number Publication date
JP2003526390A (ja) 2003-09-09
KR20010085581A (ko) 2001-09-07
ID28949A (id) 2001-07-19
AU6021099A (en) 2000-03-14
TR200202107T2 (tr) 2004-12-21
BR9913236A (pt) 2002-05-07
TR200202106T2 (tr) 2002-10-21
CN1328438A (zh) 2001-12-26
EP1107719A1 (fr) 2001-06-20
TR200100587T2 (tr) 2002-04-22
PL348227A1 (en) 2002-05-06
AU748171B2 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
US6296862B1 (en) Absorbent article which maintains or improves skin health
US6217890B1 (en) Absorbent article which maintains or improves skin health
AU748171B2 (en) Absorbent article which maintains or improves skin health
ZA200101104B (en) Absorbent article which maintains or improves skin health.
KR100957259B1 (ko) 흡수제품 착용자의 피부 건강을 위한 시스템
US6515029B1 (en) Absorbent article having a hydrophilic lotionized bodyside liner
US6149934A (en) Absorbent article having a lotionized bodyside liner
EP1345632B1 (fr) Articles absorbants obtenus a partir de compositions non aqueuses contenant des extraits de plantes
US6503526B1 (en) Absorbent articles enhancing skin barrier function
US6756520B1 (en) Hydrophilic compositions for use on absorbent articles to enhance skin barrier
US6689932B2 (en) Absorbent articles with simplified compositions having good stability
US20020120242A1 (en) Absorbent articles with hydrophilic compositions containing botanicals
US20020120241A1 (en) Absorbent articles with hydrophilic compositions containing anionic polymers
US7154018B2 (en) Absorbent article
MXPA01012649A (es) Distribucion de un substrato sacrificial para inhibir la permeacion de proteasas en la piel.
US20030130635A1 (en) Absorbent articles with compositions having even distribution
MXPA01002012A (en) Absorbent article which maintains or improves skin health
KR20020046400A (ko) 피부보호제를 함유하는 일회용 흡수제품
MXPA01009991A (en) Absorbent article having a hydrophilic lotionized bodyside liner
MXPA01009990A (en) Absorbent article having a lotionized bodyside liner

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99812602.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001/01104

Country of ref document: ZA

Ref document number: 200101104

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 60210/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/238/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/002012

Country of ref document: MX

Ref document number: 2001/00587

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1020017002351

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1999967816

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999967816

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017002351

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002/02106

Country of ref document: TR

Ref document number: 2002/02107

Country of ref document: TR

WWG Wipo information: grant in national office

Ref document number: 60210/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999967816

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017002351

Country of ref document: KR